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Steady State and Theoretical investigations of Peptidylyglycine α-Amidating Monooxygenase  
 
Edward W. Lowe, Jr. 
 
ABSTRACT 
 
Approximately 50% of all known peptide hormones are post-translationally modified at 
their C-terminus.  These peptide hormones are responsible for cellular functions critical to 
survival.  Peptidylglycine α-amidating monooxygenase (PAM) is a bi-functional enzyme which 
catalyzes the conversion of peptide pro-hormones to peptide hormones.  PAM is the only known 
mammalian enzyme that catalyzes the necessary a-amidation to activate these peptide hormones. 
PAM has previously been found to perform N-dealkylation, as well as O-dealkylation.  
We report here that a novel chemistry for PAM, S-dealkylation, has now been shown.  PAM was 
able to catalyzes the hydroxylation and subsequent dealkylation for a series of substituted 2-
(phenylthio)acetic acid analogs, leaving a product containing a free thiol capable of coordinating 
to copper(I). 
A series of cinnamic acid derivatives have been investigated as turnover dependent 
inactivators of PAM.  It was shown that the inactivating compounds contained electron donating 
substituents.  All compounds bound competitively versus substrate, though no catalytic activity 
was noted when tested as substrates.  Although no Dkinact was observed when using perdeuterated 
cinnamic acid, one cannot rule out hydrogen abstraction from the Cα as this step may not be rate 
limiting for inactivation.  This suggests that the activated oxygen species generated at CuM may 
be sufficiently reactive to abstract a hydrogen from an alkene to generate a vinyl radical.   
xi 
 
Substrate activation is believed to be facilitated by a Cu(II)-superoxo complex formed at 
CuM.  Hydrogen abstraction from the Cα is hypothesized to generate a radical, though this has 
never been demonstrated spectrometrically.  We report here further evidence for the generation 
of a Cα radical by comparing log(Vmax/KO2) vs σ+ for a series of ring-substituted 4-phenyl-3-
butenoic acids. 
Lastly, a computational study was carried out to probe for a possible binding pocket for 
the reductant, ascorbate.  Though crystal structures have argued that reduction of the enzyme-
bound coppers is collisional, kinetic data for inhibitors competitive against ascorbate indicates 
that a discrete binding pocket may exist.  Our study suggests a specific site for binding and 
provides free energy calculations in agreement with experimental values for binding constants
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Peptide Hormones 
 Approximately 50% of all known mammalian peptide hormones are α-amidated.  In 
insects, over 90% of peptide hormones are α-amidated.  The amino acid prohormone sequence of 
these peptides contains a C-terminal glycine.  The amidation of the carboxy-terminus is essential 
for activation of these peptide hormones as the glycine-extended precursors are generally >1000-
fold less potent than the α-amidated peptides [1].  Some of these amidated hormones act as 
neurotransmitters.  Many α-amidated peptide hormones have been found to be over-expressed in 
human disease states such as substance P in rheumatoid arthritis [2, 3], luteinizing hormone-
releasing hormone and vasoactive intestinal peptide in cancer[4, 5], and corticotropin-releasing 
factor in anxiety and depression[6].  The fact that the precursor sequences for these essential 
amidated hormones all contained a C-terminal glycine suggested that the C-terminal amide 
biosynthesis required the action of a specific enzyme to activate these peptide prohormones 
through the functionalization of the glycine (Figure 1.1).  In 1982, the enzyme responsible for the 
conversion of glycine-extended peptides to the corresponding peptide-amide was discovered in 
porcine pituitary[7]. 
PAM: The α-Amidating Enzyme 
 Peptidylglycine α-amidating monooxygenase (PAM) is a bifunctional copper-
monooxygenase.  PAM is found within neuronal and endocrine cells, neurosecretory vesicles, 
and the highest concentrations are found in the atrium of the heart [8-11].  PAM is primarily 
responsible in vivo for the activation of peptide hormones through the conversion of the glycine-
extension to the corresponding amide.  PAM also plays a role in the biosynthesis of fatty acid 
amides [12-15].  PAM is the only mammalian enzyme known to catalyze this amidation reaction.   
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 PAM (E.C. 1.14.17.3) consists of two hetero-domains which are peptidylglycine α-
hydroxylating monooxygenase (PHM) and peptidylglycine amidoglycolate lyase (PAL) (Figure 
1.2).  The PHM domain has been deeply studied primarily due to its similarity in both reaction 
and structure to another copper-dependent monooxygenase, dopamine β-monooxygenase [16, 
17].  Dopamine β-monooxygenase (DβM, E.C. 1.14.17.1) catalyzes the stereospecific conversion 
of dopamine to norepinephrine (Figure 1.3) [16, 18].  This tetrameric protein exists in both 
membrane and soluble forms within neurosecretory vesicles of the sympathetic nervous system 
[19].  While dopamine is a neurotransmitter in the central nervous system, its functionalization to 
norepinephrine by DβM allows for its functioning in the sympathetic nervous system which 
consists of neuronal axons that interact with smooth muscle and the catecholamine secreting 
cells within the adrenal medullae [20]. 
PHM and DβM 
  PHM and DβM are stru ctu rally similar.  The en zymes share a 2 8 % id entity and 4 0 % 
sequence similarity in the catalytic core [17, 21].  Both contain a large, solvent accessible active 
site flanked by two non-coupled copper atoms [22-24].  PHM catalyzes the copper-, O2-, and 
ascorbate-dependent hydroxylation of a glycyl Cα while DβM catalyzes the copper-, O2-, and 
ascorbate-dependent hydroxylation of a benzylic carbon (Figure 1.4) [16, 22, 25-27].  While 
PHM has been successfully crystallized, DβM has not [28].  The crystal structure of PHM 
reveals it to be a prolate ellipsoid composed of two 9-stranded β-sandwich domains (Figure 1.5).  
The domains are approximately of equivalent size and are held together by a 500 Å2 interface.  
The active site is a large, solvent accessible cleft residing at the interdomain interface with two 
bound coppers, one on each side of the cleft (Figure 1.6).  Each domain is centered around their 
respective copper atom.  Each of the two coppers has a different ligand set.  One copper center, 
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CuM, has two histidine Nε ligands and a methionine sulfur ligand (H242, H244, M314).  The 
remaining copper center, CuH, has three histidine Nδ ligands (H107, H108, H172) (Figure 1.7).  
This is also the case in DβM as one copper is coordinated to three histidines and the other to two 
histidines and a methionine.  The enzyme was co-crystallized with N-acetyl-3,5-diiodotyrosyl-
threonine, a poor substrate for PHM.  The substrate appears to form a salt bridge between the 
carboxy-terminus and the guanidino group of arginine 240 (Figure 1.8).  This places the substrate 
in close proximity to the CuM where O2 has been found to bind and where activation of O2 is 
thought to occur.  Hydrogen bonding between the glycyl amide-hydrogen and the side chain 
oxygen of N316 also plays a role in the proper positioning of the substrate.  Crystal structures for 
oxidized, reduced, and pre-catalytic forms of PHM with substrate bound have been solved [28-
30].  The crystal structures are surprisingly identical with no differences seen between the 
oxidized and reduced form and an rmsd value of 0.27 (Figure 1.9).  This suggests that movement 
or closure of the active site during catalysis does not occur.  These structures also revealed that 
the copper atoms are ~10.6 Å apart which is in good agreement with previous extended X-ray 
absorption fine structure (EXAFS) data for DβM which suggested the copper atoms were more 
than 4 Å apart [21, 28, 30-32].  These data along with electron paramagnetic resonance (EPR) 
data suggests that PHM and DβM are non-coupled di-copper enzymes or ‘non-blue’/type-II 
enzymes [22, 33, 34].  The geometries of the two copper sites were found to change upon 
reduction.  CuM is observed to have a square pyramidal geometry while in the oxidized form 
while CuH is square planar.  Upon reduction, CuM becomes tetrahedral and CuH becomes T-
shaped.  The bond length of CuM-SM314 has been shown to tighten in the reduced form compared 
to oxidized enzyme according to EXAFS data suggesting that the oxidized form is more distorted 
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tetrahedral than square planar  [34].  EXAFS data also suggests that CuH is coordinated to only 
two of the three histidine residues in the reduced form.   
 Both PHM and DβM catalyze very similar reactions.  The PHM reaction involves 
hydrogen abstraction from a substrate by some activated Cu-O species followed by the 
subsequent stereospecific hydroxylation of the pro-S g lycyl Cα.  The DΒM reaction also 
involves the abstraction of hydrogen, but does so from a benzylic carbon followed by pro-R 
hydroxylation.   In both cases, the mechanism is believed to involve electron transfer from CuH 
to CuM.   
PHM/DβM Postulated Mechanisms 
 The first step involved for catalysis is the irreversible reduction of both enzyme bound 
coppers by ascorbate allowing di-oxygen and substrate to bind to the reduced enzyme [16, 21, 
35, 36].  This reduction is a “ping-pong” mechanism.  Burst phase kinetic experiments with 
DβM have shown that pre-reduced enzyme is capable of hydroxylating substrate with the 
amplitude of the pre-steady state burst being equivalent to the concentration of enzyme [37-39].  
This indicates that the chemical step is much faster than product release and also allowed for re-
oxidation with product release to be observed.  A temperature dependence on primary and 
secondary intrinsic isotope effects for Cα-H cleavage has also been observed for PAM.  This 
non-classical behavior suggests that quantum tunneling is involved in hydrogen transfer [40].   
 18O kinetic isotope effects have been used to probe the nature of the activated Cu/O 
species responsible for hydrogen abstraction.  These studies on both PHM and DβM only 
provide information up to and including the O-O cleavage step due to the quantum mechanical 
nature of hydrogen transfer [41].  When coupled with substrate deuterium isotope effects, the 
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data for PHM and DβM indicates that C-H bond cleavage occurs prior to that of O-O necessary 
for hydroxylation [42-45].  This suggests that a Cu(II)-hydroperoxo is being formed during 
hydrogen abstraction but lends no evidence as to what the hydroxylating species may be.  Rapid 
freeze quench EPR data also suggests that a copper-superoxo species is formed, as O-O and C-H 
cleavage are tightly coupled [46].  The data suggest that the substrate intermediate resulting from 
Cu(II)-superoxo abstraction of hydrogen would be a radical intermediate.  Evidence for a radical 
mechanism has been found in DβM [47-49].  This evidence has been applied towards the PHM 
mechanism though it has not been proven directly for PHM.   
 Several competing reaction mechanisms have been proposed for PHM and DβM.  Two of 
these competing mechanisms both support a copper-superoxo nucleophile for hydrogen 
abstraction.  While the nature of the hydrogen acceptor is in agreement, the initial geometry of 
the di-oxygen species to copper is in question.  Spectroscopic data has indicated a side-on/η2 
species but was based on model studies and not PHM or DβM [50, 51].  When compared to the 
end-on/η1 species, the side-on Cu(II)-superoxo was determined computationally to be more 
thermodynamically favorable [52, 53].  However, crystallographic evidence of a pre-catalytic 
state of PHM with good resolution (1.85 Å) has found the end-on/η1 species present (Figure 
1.10) [28].  Upon forming either disputed Cu-superoxo species, both mechanisms proceed to 
abstract hydrogen to form a Cu(II)-hydroperoxo species.  This hydroperoxo species is 
coordinated to copper in an end-on/η1 geometry.  The competing mechanisms again diverge as 
the side-on/η2 mechanism predicts direct hydroxylation of the resulting substrate radical 
followed by radical recombination.  The net effect is reduction of the copper(II)-hydroperoxo 
species and release of the hydroxylated product.  Electron transfer would then occur from CuH to 
complete the reaction.   
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 On the other hand, the end-on/η1 mechanism postulates that the Cu(II)-hydroperoxo 
species is reduced by an electron transfer event prior to hydroxylation of the substrate radical.  
This electron provided by the CuH site allows for homolysis of the Cu(II)-O-OH yielding a 
Cu(II)—O• species.  This newly formed Cu/O• would then recombine with the substrate radical 
intermediate resulting in a covalent, inner-sphere alcohol intermediate.  Product release then 
occurs via hydrolysis of this intermediate.  The proposed mechanisms are compared in Figure 
1.11. 
 While experimentalists agree that the hydrogen abstracting species is, indeed, a copper-
superoxo, several theoreticians have proposed that a different activated Cu/O species is 
responsible for this chemistry.  Using a series of molecular dynamics (MD) and mixed quantum 
mechanics molecular mechanics (QM/MM) calculations, two separate mechanisms have been 
proposed.  The species proposed as responsible for hydrogen abstraction is a reduced copper-
oxo.  This suggests that di-oxygen reduction and substrate activation are uncoupled which is in 
direct contrast to experimental data.  QM/MM simulations suggest that Cu(III)-oxide/Cu(II)-oxyl 
species are thermodynamically favored over the superoxo/hydroperoxo species proposed by 
experimentalists [54-56].  These theoretical mechanisms suggest that electron transfer precedes 
hydrogen abstraction allowing Cu(II)-superoxo to acquire two protons from solvent.  Water is 
then released from the Cu(II)-O-OH2 species leaving either a Cu(II)-oxyl quartet or a Cu(II)-oxyl 
triplet species to abstract hydrogen from the substrate.  The quartet is proposed to concertedly 
abstract the substrate hydrogen and hydroxylate the radical intermediate with a spin inversion to 
the doublet ground state occurring upon substrate oxidation[54].  This suggests that substrate 
oxidation and product release happen simultaneously.  A water molecule would then bind to the 
remaining Cu(II) to restore proper geometry in the oxidized state.  The triplet Cu(II)-oxyl is 
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believed to undergo a spin inversion event to the singlet ground state upon substrate C-H 
oxidation driving concerted product release [55, 56].  These two theoretical mechanisms are 
compared in Figure 1.12. 
Peptidylglycine Amidoglycolate Lyase 
 The lyase domain in PAM responsible for carbinolamide dealkylation of the α-
hydroxyglycine PHM product resulting in the corresponding amide and glyoxylate is the PAL 
domain.  This 33 kDa monomer is zinc-, calcium-, and iron-dependent and bound to the C-
terminus of the PHM domain.  Although the complete PAL mechanism is unknown, it is 
believed to proceed through a zinc-hydrolase-type reaction [57].  The iron is involved in a 
tyrosine bridged Zn(II)-Fe(III) complex.  Mutation of this tyrosine (Y564) results in PAL 
inactivation and the inability to bind iron.  No substrate channeling between PHM and PAL has 
been observed.  While the inclusion of the PAL domain in PAM provides the key difference 
between PAM and DβM, DβM has also been noted to catalyze several N-dealkylation reactions 
solely through hydroxylation like that of benzylic N-substituted analogues [58].  PAM and DβM 
have also both demonstrated sulfoxidation while PAM has demonstrated O-dealkylation [59].   
Introduction to Chapters 
 PAM has previously been found to perform N-dealkylation, as well as O-
dealkylation.  We report here that a novel chemistry for PAM, S-dealkylation, has now been 
shown.  PAM was able to catalyzes the hydroxylation and subsequent dealkylation for a series of 
substituted 2-(phenylthio)acetic acid analogs, leaving a product containing a free thiol capable of 
coordinating to copper(I). 
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A series of cinnamic acid derivatives have been investigated as turnover dependent 
inactivators of PAM.  It was shown that the inactivating compounds contained electron donating 
substituents.  All compounds bound competitively versus substrate, though no catalytic activity 
was noted when tested as substrates.  Although no Dkinact was observed when using perdeuterated 
cinnamic acid, one cannot rule out hydrogen abstraction from the Cα as this step may not be rate 
limiting for inactivation.  This suggests that the activated oxygen species generated at CuM may 
be sufficiently reactive to abstract a hydrogen from an alkene to generate a vinyl radical.   
Substrate activation is believed to be facilitated by a Cu(II)-superoxo complex formed at 
CuM.  Hydrogen abstraction from the Cα is hypothesized to generate a radical, though this has 
never been demonstrated spectrometrically.  We report here further evidence for the generation 
of a Cα radical by comparing log(Vmax/KO2) vs σ+ for a series of ring-substituted 4-phenyl-3-
butenoic acids. 
Lastly, a computational study was carried out to probe for a possible binding pocket for 
the reductant, ascorbate.  Though crystal structures have argued that reduction of the enzyme-
bound coppers is collisional, kinetic data for inhibitors competitive against ascorbate indicates 
that a discrete binding pocket may exist.  Our study suggests a specific site for binding and 
provides free energy calculations in agreement with experimental values for binding constants. 
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Figure 1.1. Pro-substance P converted to the bioactive substance P through some amidation 
mechanism. 
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Figure 1.2. PAM reaction scheme showing the roles of both PHM and PAL. 
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Figure 1.3. The dopamine β-monooxygenase reaction scheme. 
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Figure 1.4. The reaction schemes of PHM (left) and DβM (right). 
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Figure 1.5. PHM crystal structure (reduced) in licorice representation.  Note, carbons are 
teal, oxygens are red, nitrogens are blue, sulfurs are yellow, and hydrogens are not shown 
for clarity. 
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Figure 1.6. PHM crystal structure shown with bound coppers flanking the active site. 
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Figure 1.7. The two copper centers in the PHM crystal structure coordinated to their 
respective 3-ligand system.  Note, only the side chains of the residues are shown methyl-
capped. 
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Figure 1.8. PHM crystal structure with IYT forming a salt-bridge with R240. 
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Figure 1.9. PHM crystal structures of reduced (red) and oxidized (blue) forms aligned show 
very little differences in structure versus redox state (Rmsd = 0.27 Å). 
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Figure 1.10. The pre-catalytic PHM crystal structure with oxygen bound to CuM in end-on 
fashion. 
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Figure 1.11. The two mechanisms proposed from experimental data are compared with the 
side-on/n2 mechanism above and the end-on/n1 mechanism below. 
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Figure 1.12. The two mechanisms proposed by theoreticians are compared with the quartet 
to doublet spin inversion above and the triplet to singlet spin inversion below. 
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Introduction 
 Peptidylglycine α-amidating monooxygenase (PAM) catalyzes the oxidative cleavage of 
C-terminal glycine-extended peptide hormones[1], fatty acid precursors [2-5], and bile acids [6] 
to the corresponding amides and glyoxylate.  This two-step amidation proceeds via a copper-, 
O2-, and ascorbate-dependent glycyl Cα hydroxylation followed by a zinc-, iron-, and calcium-
dependent dealkylation of the carbinolamide intermediate (Figure 2.1).  This bifunctional nature 
is attributable to the peptidylglycine α-hydroxylating monooxygenase (PHM) and 
peptidylglycine amidoglycolate lyase (PAL) domains, respectively [7, 8].  This α-amide moiety 
is a requisite for most active peptide hormones, with the amidated derivatives generally 
displaying >1000-fold more potency than the glycine-extended precursor[1].  PAM is 
responsible for the activation of many important neuropeptides such as substance P and oxytocin 
[9-11].  While this is the primary in vivo function of PAM, alternate catalytic functions have 
been reported including sulfoxidation, and O-dealkylation [12].   
PAM/PHM is a potential therapeutic target because of the roles played by α-amidated 
peptides in disease states.  Some examples of α-amidated peptides implicated in disease are 
luteinizing hormone-releasing hormone (cancer), vasoactive intestinal peptide (cancer), 
substance P (rheumatoid arthritis), and corticotropin-releasing factor (anxiety and depression).  
Because prevention of amidation often reduces the efficacy of peptide hormones by ~3 orders of 
magnitude, broad inhibition of PAM may be overly toxic by blocking the conversion of essential 
mammalian α-amidated peptides.   
Toxicity may, however, prove useful in the possible development of insecticides.  Insects 
possess separate PHM and PAL monomers and lack the bi-functional PAM enzyme [13, 14].  
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Elimination of expression in Drosophila melanogaster has been demonstrated to be lethal [14].  
Because the mammalian PHM sequence and Drosophila PHM sequence share 41% identity and 
52% similarity, sufficient differences may exist to target only the insect enzyme.  
Several (2-phenylthio)acetic acid (PTAA) derivatives were investigated as inhibitors of 
PAM activity.  PTAA displays characteristics of a turnover-dependent inactivator of PAM.  We 
now report that PAM can catalyze S-dealkylation.  This S-dealkylation leaves a free thiol capable 
of in situ coordination of the active site CuM leading to reversible inactivation of PAM.  This 
discovery may give a new direction for the design of PAM inhibitors.  The S-Cα moiety allows 
for the design of PAM specific pro-drugs that rely on PAM turnover for drug activity.   
MATERIALS AND METHODS 
Materials.   
 [(1-H-indole-2-ylcarbonyl)thiol]acetic acid and 2-(phenylthio)acetic acid were purchased 
from Sigma, 2-(4-chlorophenylthio)acetic acid was purchased from Pfaltz & Bauer, Inc., 2-(4-
methylphenylthio)acetic acid was purchased from Aldrich Chem. Co., 2-(benzoylthio)acetic 
acid, 2-(2-nitrophenylthio)acetic acid, N-benzoyl-D-alanylthioglycolic acid were purchased from 
Eburon Organics N.V., and bovine catalase was from Worthington.  Recombinant rat PAM was a 
gift from Unigene Laboratories, Inc. All other reagents were of the highest quality from 
commercial suppliers. 
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Synthesis of α-di-deutero-2-(phenylthio)acetic acid  
 Thiophenol (6.1 mL, 60 mmol) in aqueous sodium hydroxide (20 mL 6M) was reacted 
with (α-D,D) bromoacetic acid (12.5 gm, 90 mmol) for 2 hr at 50 oC.  The reaction was then 
acidified with dilute HCl(aq), precipitate collected, and re-crystallized twice in hot ethanol. 
Determination of KM,app and VMAX,app values for 2-(phenylthio)acetic acid (α-H,H and α-D,D), 2-
(4-methylphenylthio)acetic acid, 2-(4-chlorophenylthio)acetic acid, and 1-H-indole-2-
ylcarbonyl)thiol]acetic acid.   
 Reactions at 37.0 ± 0.1 °C were initiated by the addition of PAM (20-50 µg) into 2.0 ml 
of 100 mM MES/NaOH pH 6.0, 30 mM NaCl, 1% (v/v) ethanol, 0.001% (v/v) Triton X-100, 10 
µg/ml bovine catalase, 1.0 µM Cu(NO3)2, 5.0 mM sodium ascorbate, and 0.1 – 6.0 mM of the 
oxidizable substrate.  Initial rates were measured by following the PAM-dependent consumption 
of O2 using a Yellow Springs Instrument Model 5300 oxygen monitor interfaced with a personal 
computer using a Dataq Instruments analogue/digital converter (model DI-158UP).  VMAX,app 
values were normalized to controls performed at 11.0 mM N-acetylglycine. 
Inhibition of O2 consumption from N-acetylglycine by 2-(phenylthio)acetic acid  Reactions at 
37.0 ± 0.1 °C were initiated by the addition of PAM (35 µg) into 2.0 ml of 100 mM MES/NaOH 
pH 6.0, 30 mM NaCl, 1% (v/v) ethanol, 0.001% (v/v) Triton X-100, 10 µg/ml bovine catalase, 
1.0 µM Cu(NO3)2, 5.0 mM sodium ascorbate, 8 mM N-acetylglycine, and 0-5 mM 2-
(phenylthio)acetic acid.  Initial rates were measured by following the PAM-dependent 
consumption of O2 using a Yellow Springs Instrument Model 5300 oxygen monitor. 
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Glyoxylate production from 2-(phenylthio)acetic acid derivative substrates   
 To first determine if the PHM-hydroxylated 2-(phenylthio)acetic acid was a substrate for 
PAL, 20 µg of PAM was added to a 2.0 mL of 100 mM MES/NaOH pH 6.0, 30 mM NaCl, 1.0% 
(v/v) ethanol, 0.001% (v/v) Triton X-100, 10 µg/mL catalase, 1.0 µM Cu(NO3)2, 5.0 mM sodium 
ascorbate, and 10 mM 2-(phenylthio)acetic acid.  After incubation for 2 hr. at 37°C, the reaction 
was terminated by the addition 500 µL of 6% (v/v) TFA and duplicate 500 µL aliquots were 
removed for glyoxylate analysis.  
Initial rates of glyoxylate formation from 2-(phenylthio)acetic acid were determined by 
adding 20 µg of PAM to a 3.0 mL solution containing 100 mM MES/NaOH pH 6.0, 30 mM 
NaCl, 1.0% (v/v) ethanol, 0.001% (v/v) Triton X-100, 10 µg/mL catalase, 1.0 µM Cu(NO3)2, 5 
mM sodium ascorbate, and 10 mM 2-(phenylthio)acetic acid. At 30 min. intervals for 150 min., a 
500 µL aliquot was removed, added to a vial containing 100 µL of 6% (v/v) TFA to terminate 
the reaction, and the concentration of glyoxylate formed measured in the acidified samples.     
Initial rates of glyoxylate formation from α-hydroxyhippurate, a known PAL substrate, as 
a function of the 2-(phenylthio)acetic acid concentration were determined by adding 20 µg of 
PAM to a 1.5 mL solution containing 100 mM MES/NaOH pH 6.0, 30 mM NaCl, 1.0% (v/v) 
ethanol, 0.001% (v/v) Trition X-100, 10.0 mM α-hydroxyhippurate, and 0-10.0 mM 2-
(phenylthio)acetic acid.  At 10 min. intervals from 10 to 60 min., a 100 µL aliquot was removed, 
added to a vial containing 20 µL of 6% (v/v) TFA to terminate the reaction, and the 
concentration of glyoxylate formed measured in the acidified samples. 
Glyoxylate was determined by the spectrophotometric method of Christman et al. [15] as 
modified by Katopodis and May [12].  Standard curves of [glyoxylate] vs. A520 were constructed 
in the appropriate buffers using a glyoxylate solution that had been standardized by measuring 
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the glyoxylate-dependent oxidation of NADH (∆ε340 = 6.22 x 10
3
 M
-1
 cm
-1
) as catalyzed by 
lactate dehydrogenase. 
RP-HPLC separation of 2-(phenylthio)acetic acid and thiophenol.   
 HPLC analyses were performed using a Hewlett-Packard 1100 liquid chromatography 
system equipped with an auto-sampler and quaternary pump system.  Aliquots (10 µL) of the 
reaction mixture were analyzed using a Phenomenex Luna 5µ C18 (250 x 4.60 mm) column.  The 
mobile phase was a linear 70-100% gradient of 50 mM sodium acetate pH 6/acetonitrile (85/15) 
in acetonitrile.  Analytes were detected at 254 nm.   
Analysis of steady-state kinetic data   
 Steady-state kinetic parameters were obtained by Kaleidagraph fit of the initial velocity 
(v) vs. substrate concentration, ([S]), data to 
                                                         (1) 
Where KM,app is the apparent Michaelis constant for the oxidizable substrate at fixed [ascorbate] 
and [O2] concentrations and VMAX,app is the apparent maximum initial velocity at saturating [S]. 
Initial rate studies that resulted in competitive inhibition were also analyzed by Kaleidagraph fit 
of v vs. [S] as a function of inhibitor concentration to equation 2.   
                   (2) 
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In silico docking   
 The crystal structure for reduced peptidylglycine α-hydroxylating monooxygenase 
(PHM) was obtained from the Protein Data Bank (http://www.rcsb.org/pdb/, 1SDW) [16].  All 
co-crystallized species determined to be redundant for ligand binding were removed (nickel, 
water, glycerol, and substrate).  Formal charges for enzyme-bound copper ions and bond orders 
were corrected, and hydrogens were added using Maestro (www.schrodinger.com).  Further 
receptor refinements were carried out utilizing ProteinPrep from within Maestro.  Glide and Q-
site from the FirstDiscovery 3.0 suite (www.schrodinger.com) were used for quantum polarized 
ligand docking (qpld) to generate highly accurate ligand binding modes [17, 18].   
Computational Chemistry   
 The top pose from the in silico docking studies of thiophenolate was used as input for the 
geometry optimization of the L3Cu-thiophenolate system.  The CuM ligand set, H242, H244, and 
M314, were truncated to methyl-capped side chains to lessen the computational expense of 
geometry optimizing the system.  Three systems were thus created.  System 1 included the 
previously mentioned methyl-capped side chains, Cu1+, and a single water molecule coordinated 
to the copper (Figure 2.2).  System 2 included, once again, the L3Cu1+ system, but the 
coordinated water was replaced by the qpld docked thiophenolate (Figure 2.3).  The final system, 
System 3, contained only the three-residue CuM coordination site along with Cu1+ (Figure 2.4).  
The geometries of these two systems were optimized using density functional theory with 
B3LYP hybrid exchange-correlation and the LanL2DZ+ECP basis set [19-21].   
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RESULTS AND DISCUSSION 
2-(phenylthio)acetic acid as a PAM substrate   
 The addition of PAM to solutions containing p-Cl-PTAA resulted in the consumption of 
O2 (Figure 2.5).  The dependence of the initial rate of O2 consumption on the initial concentration 
of PTAA, at a fixed concentration of reductant and O2, is described by equation 1 yielding the 
steady-state kinetic values for KM,app, VMAX,app, and (V/K)app included in Table 2.1.  Investigation 
of α-d,d-PTAA gave a D(V/K)app isotope effect of 1.9 giving further proof that the Cα-H bond 
cleavage was occuring.  Incubation of 10 µg/mL PAM with 10 mM PTAA for 1 hr at 37 oC 
yielded 96 µM glyoxylate verifying that PTAA is indeed a substrate and alluding to the 
inactivating species, thiophenol (Figure 2.6).   
2-(phenylthio)acetic acid derivatives as PAM substrates and inhibitors   
 The pattern of O2 consumption observed for all PTAA-related substrates appeared 
characteristic of that of a mechanism-based inhibitor indicating turnover followed by enzyme 
inactivation.  Because this inactivation was slow, analyses of initial rates in obtaining the steady-
state kinetic parameters is valid.  Glyoxylate was also produced in all instances.  Those 
compounds in which glyoxylate was not produced, however, neither consumed O2 nor 
inactivated PAM.  The derivatives which did not consume O2 when tested as substrates did 
inhibit O2 consumption from N-acetylglycine (Figure 2.7) yielding the steady-state kinetic values 
as described by equation 2 (Table 2.2).  LC/MS of trypsin-digested PAM after incubation with 
PTAA showed no labeling (data not shown) suggesting that the enzyme was not being covalently 
modified as is typical of a mechanism-based inhibitor.  LC/MS analysis did, however, indicate 
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that thiophenol was being produced.  An HPLC separation was then developed and thiophenol 
was successfully found in the reaction mixture (Figure 2.8) 
Product-mediated reversible inactivation   
 Thiophenol is a known Cu1+ chelator and interacts more weakly with Cu2+.  It was 
hypothesized that the thiophenol product either coordinate to active site copper, forming an E-
2Cu(II)/(I)·inhibitor complex, or removes the active site copper, forming a copper-free-E and 
separate Cu(II)/(I)·inhibitor complexes.  The copper free form of PAM is inactive [22, 23].  This 
type of thiol-mediated inhibition is well-documented in both PAM and related enzyme dopamine 
β-monooxygenase (DβM), both copper-dependent monooxygenases [24-27].  The inhibition of 
PAM by homocysteine-extended peptides [28] and by captopril [29] has been attributed to 
sulfur-copper interactions.  The inhibition of DβM by captopril, and glutathione has been 
attributed to in situ chelation of the enzyme-bound coppers [30, 31].  If in situ chelation were 
occurring, out-competing the S-Cu interaction leaving the enzyme-bound copper free to once 
again support catalysis should be possible.  Thus, a reaction was initiated with 20 µg of PAM 
under the previously mentioned condition for monitoring O2 consumption and 5 mM 2-(4-
chlorophenylthio)acetic acid.  Upon observing the inactivation of PAM, with the rate of O2 
consumption matching that of the background prior to initiating the reaction with enzyme, the 
reaction was spiked with HgCl2 to a final Hg2+ concentration of 5 µM.  This caused a resumption 
of O2 consumption of 2 µM, leading to the supposition that the stronger Hg-S interaction was 
relieving the enzyme-bound copper of the proposed chelating species, thiophenol (Figure 2.9). 
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Modeling of PTAA, analogs, and thiophenol in the PHM active site   
 The X-ray structures of oxidized and reduced PHM, the subunit responsible for 
catalyzing the copper-dependent glycyl Cα hydroxylation, reveal that the enzyme-bound coppers 
are ~11Å apart flanking a solvent-accessible active site cleft [16, 24].  CuH and CuM, named for 
their respective ligands of three histidines (CuH), and two histidines and a methionine (CuM), 
have different roles in catalysis as CuH is involved in electron transfer while CuM is the site of O2 
activation and substrate hydroxylation.  Utilizing the crystal structure of reduced PHM in a pre-
catalytic state with O2 coordinated to CuM and a substrate analog in the active site (Figure 2.10), 
we were afforded an excellent opportunity to model the sulfur-containing compounds and the 
proposed product responsible for in situ chelation, thiophenol.   
 The reduced PHM crystal structure, 1SDW [16], was chosen for the docking studies.  All 
ligands were docked along with the proposed thiophenol product and the thiophenolate species 
(C6H5S-), L and L- respectively.  This thiolate species should account for ~20% of the product 
under reaction conditions, pH 6.0.  All of the analogs bound similarly to the reduced PHM 
crystal structure, displaying a salt bridge of the carboxy terminus to the guanidine group of R240 
similar to that of the natural glycine-extended substrates of PHM [24].  The greatest dissimilarity 
in binding modes with that of the biological substrate is the absence of the glycyl amide 
hydrogen bonding to the oxygen of N316 [24].  This interaction plays a large role in proper 
positioning of the Cα-H for H abstraction (Figure 2.11).  
Coordination of CuM by thiophenol 
 The binding mode from the qpld docking of thiophenolate was used as the starting 
structure for the geometry optimization as indicated in the Materials and Methods section. The 
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optimized geometries for the coordination of Cu1+ to the three residue coordination site in the 
CuM domain were compared between the L3Cu1+-H2O system, the L3Cu1+ system, and the 
L3Cu1+-thiophenolate system to investigate coordination stability and to determine whether the 
coordination of the thiophenolate would disrupt the L3Cu1+ stability.  The L3Cu1+ uncoordinated 
system is as expected with coordination distances of 2.01, 1.98, and 2.43 Å to NH242,NH244, and 
SM314 respectively (Figure 2.12).  The L3Cu1+-H2O geometry optimized system displaced a 
tetrahedral geometry with coordination distances of 2.05, 2.01, 2.52, and 2.19 Å for NH242, NH244, 
SM314, and H2O respectively (Figure 2.13).  This geometry is in good agreement with 
experimental values for this coordination state in the CuM domain.  The geometry optimization 
for the final system revealed something unexpected.  The thiophenolate anion disrupted the 
geometry of the CuM and changed the coordination number of the system.  The geometry shifts 
from the typical slightly distorted tetrahedral from the water coordinated system to a trigonal 
pyramidal 3-coordinate system with the SM314 4.75 Å away from CuM (Figure 2.14).  The other 
coordination distances are 2.13, 2.08, and 2.38 for NH242, NH244, and S-thiophenolate 
respectively.  This change in coordination number and geometry would greatly reduce the chance 
of oxygen activation. 
Conclusion 
 In conclusion, we have shown that PAM can catalyze the dealkylation of the R-S-Cα 
moiety leaving a free thiol/thiolate capable of in situ coordination to enzyme-bound copper.  
Recent work by the Merkler group has demonstrated that the inclusion of a sulfur atom in small 
molecule inhibitors of PAM increases binding affinity regardless of oxidation state (in press).  
The present work suggests that a pro-drug could be developed allowing PAM to catalyze the 
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production of the free thiol thus greatly reducing the possibility for unintentional free thiol 
interactions with other metallo-enzyme prior to contact with PAM.   
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List of Figures 
 
Figure 2.1. The reactions catalyzed by PHM and PAL.  Bifunctional PAM is composed of 
the two monofunctional enzymes.  The possible role of Fe(III) in PAL catalysis is unclear. 
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Figure 2.2. The CuM domain with the L3 side chains methyl-capped and a single water 
molecule coordinated to Cu1+.  Note, the carbons are displayed in teal, the nitrogens in 
blue, the hydrogens in white, the oxygen in red, the sulfur in yellow, and the copper in 
orange.   
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Figure 2.3. The CuM domain with the L3 side chains methyl-capped and thiophenolate 
coordinated to Cu1+.  Note, the carbons are displayed in teal, the nitrogens in blue, the 
hydrogens in white, the oxygen in red, the sulfur in yellow, and the copper in orange.   
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Figure 2.4. The CuM domain with the L3 side chains methyl-capped and coordinated to 
Cu1+.  Note, the carbons are displayed in teal, the nitrogens in blue, the hydrogens in white, 
the oxygen in red, the sulfur in yellow, and the copper in orange.   
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Figure 2.5. The PAM-Dependent Consumption of O2 in the Presence of 2-(4-
chlorophenylthio)acetic acid. O2 consumption at 37°C was initiated by the addition of 20 μg 
of PAM (A) to a 2.0 mL solution containing 100 mM MES/NaOH pH 6.0, 30 mM NaCl, 
1.0% (v/v) ethanol, 0.001% (v/v) Triton X-100, 10 μg/mL catalase, 5.0 mM sodium 
ascorbate, and 5 mM 2-(4-chlorophenylthio)acetic acid.  O2 consumption was measured as 
described in the materials and methods section.  Note that the background rate has been 
removed for clarity. 
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Figure 2.6. Proposed 2-(phenylthio)acetic acid cleavage by PAM mechanism.  Cα 
hydroxylation (PHM) and subsequent S-Cα cleavage (PAL) produce thiophenol and 
glyoxylate.  Thiophenolate is a known Cu1+ coordinator. 
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Figure 2.7. Inhibition of PAM by 2-(benzoylthio)acetic acid. Initial rates were determined 
at 37 °C as described in the Materials and Methods section. The points are the 
experimentally determined initial rates and the curve was drawn using the constants 
obtained by computer fit to eq. 2. The error bars represent the standard deviation of 
duplicate measurements of the initial rates. 
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Figure 2.8. RP-HPLC analysis of PAM reaction containing PTAA as the substrate.  The 
mobile phase was a linear 70-100% gradient of 50 mM sodium acetate pH 6/acetonitrile 
(85/15) in acetonitrile.  The chromatograms shown are a thiophenol standard, a 2-
(phenylthio)acetic acid standard, and a reaction mixture after treatment with PAM, 
respectively.  Analytes were detected at 254 nm.   
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Figure 2.9. Effects of mercury competition with thiol for copper on O2 consumption.  The 
reaction was prepared as indicated in the Materials and Methods section for monitoring 
oxygen consumption.  Upon initiation of the reaction with the addition of PAM (A), the 
reaction went to completion which is indicated by the slope of oxygen consumption 
matching that of the background rate prior to the addition of enzyme.  The sample was 
then spiked with HgCl2 to a final concentration of 5 µM (B).  Oxygen consumption then 
resumed until 1.2 µM of additional oxygen had been consumed. Note that the background 
rate has been removed for clarity. 
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Figure 2.10. PHM crystal structure.  The 1SDW PHM crystal structure with the secondary 
structure rendered as a ribbon.  The copper is depicted in orange, the bound molecular 
oxygen in red, and the substrate IYT rendered in tube format colored by atom 
(red=oxygen, green=iodine, teal=carbon, blue=nitrogen). 
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Figure 2.11. PTAA and N-benzylglycine docked into the PHM crystal structure.  (A) PTAA 
was docked into the PHM crystal structure (1SDW).  The carboxylate forms a salt bridge 
with the R240 guanidino as expected.  However, the absence of an amide hydrogen 
available for hydrogen bonding to the N316 oxygen allows for a great deal of movement 
and prevents proper positioning of the Cα-H for abstraction by an activated-oxygen 
species.  (B) N-benzylglycine docked for comparison to illustrate proper hydrogen bonding 
and positioning.  Non-amide hydrogens were omitted for clarity. 
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Figure 2.12. L3Cu1+ geometry optimized using the LanL2dz+ECP basis set. 
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Figure 2.13. L3Cu1+-H2O system geometry optimized with the LanL2dz+ECP basis set.  
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Figure 2.14. L3Cu1+-thiophenolate system geometry optimized with the LanL2dz+ECP 
basis set. 
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TABLES 
Table 2.1. Steady-state kinetic constants for 2-(phenylthio)acetic acid and analogs 
 
Name Structure  
KM,app 
(mM) 
Vmax,app 
(s-1) 
(VMAX/KM)app 
(mM-1 s-1) 
[(1-H-Indol-2-
ylcarbonyl)thio]acetic acid 
  
2.3 ± 0.6  0.4  ±  0.01 0.17 ± 0.05 
2-(phenylthio)acetic acid 
  
 0.95  ± 0.13  1.5  ±  0.2 1.6 ± 0.3 
α-D,D-2-(phenylthio)acetic 
acid 
  
 3.1 ±  0.6  2.6  ±  0.2    0.84 ± 0.17 
2-(4-chlorophenylthio)acetic 
acid 
  
 0.53  ± 0.11  1.8  ±  0.1 3.4 ± 0.7 
2-(4-methylphenylthio)acetic 
acid  
  
 4.2 ± 0.2  2.3  ±  0.4 0.55 ± 0.10 
H
N
S COOH
O
S COOH
S COOH
D D
S COOH
Cl
S COOH
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Table 2.2. PAM Inhibitors. 
Name Structure Kis,APP 
(mM) 
2-(benzoylthio)acetic 
acid S
O
COOH
 1.9 ± 0.1 
2-(2-
nitropheylthio)acetic 
acid 
S COOH
NO2
 0.14 ± 0.02 
N-benzoyl-D-
alanylthioglycolic acid 
 
SHOOC
H
N
O
O  0.89 ± 0.01 
 
 
 
 
 
 
 
Chapter Three: Cinnamic Acid Derivatives as Inactivators of PAM 
 
58 
 
Introduction 
Peptidylglycine α-hydroxylating monooxygenase (PHM) is a copper-, oxygen- and 
ascorbate-dependent enzyme responsible for activating glycine-extended peptide prohormones 
through an oxidative cleavage yielding the corresponding peptide amide [1-6]. This reaction 
proceeds through the abstraction of hydrogen from the glycyl Cα followed by hydroxylation of 
said Cα and finally cleavage of the amide-Cα bond resulting in glyoxyate and the peptide amide.  
This bifunctional enzyme consists of the peptidylglycine α-hydroxylating monooxygenase 
(PHM) and the zinc-, calcium-, and iron-dependent peptidylglycine amidoglycolate lyase (PAL) 
domains, responsible for the hydrogen abstraction and hydroxylation, and the hydrolysis of the 
amide-Cα bond, respectively (Figure 3.1) [7, 8].  PHM and  its sister enzy me, d op amin e β-
monooxygenase, have been studied extensively and are mechanistically similar[9].  The products 
of these reactions are essential signaling molecules which are stored in secretory granules and 
used for intercellular communication. 
 PAM activates several inflammatory hormones such as substance P.  Previous studies 
have targeted PAM using mechanism-based inactivators to inhibit carrageenan-induced edema as 
well as all three phases of adjuvant-induced polyarthritis in rats [10].  Substance P is also found 
in the spinal fluid of fibromyalgia patients, making PAM a possible drug target for such 
inflammatory diseases.  Genetically engineered mice and Drosophila lacking a functioning PHM 
gene generally die as embryos [11-13].  Thus, simply targeting PAM or PHM activity would be 
lethal.  However, with advances in tissue-specific targeted drug delivery, this will become less of 
an obstacle. 
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 Cinnamic acid and its derivatives are found in fruits, vegetables, and flowers.  Cinnamic 
acid is an intermediate in the shikimate pathway, the pathway which links carbohydrate 
metabolism to the biosynthesis of aromatic compounds in plants.  Recent studies on the utility of 
cinnamic acid derivatives as insulin releasing agents have proven certain ring-substituted 
cinnamic acids very effective in lowering plasma glucose levels [14, 15].  It has been suggested 
that cinnamic acid derivatives may be effective as treatment of diabetes mellitus for the 
regulation of blood glucose levels through the stimulation of insulin secretion [14].   
 Here we report on the investigation of several inactivators of PAM related to cinnamic 
acid.  These compounds, whose derivatives are used as food and fragrance additives, are 
structurally similar to a known suicide substrate, 4-phenyl-3-butenoic acid[16].   Our results 
demonstrate that while the inactivation is turnover-dependent, the inactivator does not undergo 
any detectible chemistry as is typical of a suicide substrate.  This finding merits further study 
into the effects of cinnamic acid inactivation of PAM in vivo as a potential drawback of using 
these molecules as diabetes therapeutics.   
Materials and Methods 
 Materials 
 Cinnamic acid, 2-trifluorocinnamic acid, 3-(3-pyridyl)acrylic acid, phenylpropiolic acid, 
3,4-methylenedioxycinnamic acid, N,N-dimethylaminocinnamic acid, maleamic acid, N-
phenylmaleamic acid, Urocanic acid, 4-aminocinnamic acid, and perdeuterated cinnamic acid 
were from Sigma.  Bovine catalase was from Worthington and 4-anilino-4-oxobut-2-enoic acid 
was from Enamine.  Recombinant rat PAM was a gift from Unigene Laboratories, Inc.  All other 
reagents were of the highest quality commercially available.   
Chapter Three: Cinnamic Acid Derivatives as Inactivators of PAM 
 
60 
 
Synthesis 
 Dansyl-4-aminocinnamic acid 
  A solution of dansyl-chloride (400 mg, 1.5 mmol) in a minimal dry pyridine (~2 mL) 
was added dropwise to a N2-purged solution of 4-aminocinnamic acid (500 mg, 3.1 mmol) in 50 
mL of dry pyridine at 60 °C.    After 24 hours, the reaction was diluted then extracted with Et2O 
(100 mL x 3), yielding a yellow oil.  Crystallization of the final dansyl-4-aminocinnamic acid 
was done with methanol/ddH2O (285 mg, 48%).  
3-phenyloxirane-2-carboxylic acid 
 Cinnamic acid (5 g, 34 mmol) dissolved in a 30 mM NaOH(aq) (~100 mL)  was combined 
with an oxone (30 g, 98 mmol) solution in H2O (100 mL).  A constant pH of six was maintained 
over six hours through the addition of NaOH then stirred for an additional 16 hours.  Acid 
extraction (pH 1) of the reaction was performed with Et2O (500 mL) by vigorously stirring the 
bi-phasic solution for ~2 hours.  The organic layer was then separated and removed under 
reduced pressure.  The resulting residue was crystallized with ethanol/H2O (1.6 gm, 29%).   
In silico ligand docking 
 The crystal structure for reduced peptidylglycine α-hydroxylating monooxygenase 
(PHM) was obtained from the Protein Data Bank (http://www.rcsb.org/pdb/, 1SDW) [17].  All 
co-crystallized species determined to be redundant for ligand binding were removed (nickel, 
water, glycerol, and substrate).  Formal charges for enzyme-bound copper ions and bond orders 
were corrected, and hydrogens were added using Maestro (www.schrodinger.com).  Further 
receptor refinements were carried out utilizing ProteinPrep from within Maestro.  Investigation 
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of inhibitor binding modes were performed using Glide[18] and Qsite[19] jointly for quantum 
polarized ligand docking.  This method generates highly accurate binding modes by quantum 
mechanically calculating the partial atomic charges of the docked ligand using B3LYP/6-31G* 
within the receptor and subsequently re-docking the ligand [20, 21].   
DFT investigation of Cα-H dissociation energies 
 The bond dissociation energies of Cα-H for all cinnamic acid analogs were calculated 
using Jaguar [22].  DFT calculations were performed with the B3LYP hybrid exchange-
correlation functional and the 6-31G* basis set.  The geometries were optimized for all 
molecules in the gas phase.  The Cα-H bond was then increased from 1.08 – 3.0 Ǻ while holding 
the molecule rigid (Figure 3.2), and single point energies were calculated  
Inhibition of O2 consumption from N-acetylglycine by cinnamic acid 
 Reactions at 37.0 ± 0.1 °C were initiated by the addition of PAM (35 µg) into 2.0 ml of 
100 mM MES/NaOH pH 6.0, 30 mM NaCl, 1% (v/v) ethanol, 0.001% (v/v) Triton X-100, 10 
µg/ml bovine catalase, 1.0 µM Cu(NO3)2, 5.0 mM sodium ascorbate, 1.0 – 45 mM N-
acetylglycine, and 0-9 mM cinnamic acid.  Initial rates were measured by following the PAM-
dependent consumption of O2 using a Yellow Springs Instrument Model 5300 oxygen monitor. 
Inactivation of PAM by cinnamic acid 
 Inactivation reactions of 100 µL containing 100 mM MES/NaOH pH 6.0, 30 mM NaCl, 
1% (v/v) ethanol, 0.001% (v/v) Triton X-100, 10 µg/ml bovine catalase, 1.0 µM Cu(NO3)2, 5.0 
mM sodium ascorbate, and 0-3 mM cinnamic acid were initiated by the addition of enzyme and 
incubated at 37 °C.  Aliquots of 15 µL were withdrawn at various intervals and diluted into 2.0 
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mL reactions containing 100 mM MES/NaOH pH 6.0, 30 mM NaCl, 1% (v/v) ethanol, 0.001% 
(v/v) Triton X-100, 10 µg/ml bovine catalase, 1.0 µM Cu(NO3)2, 5.0 mM sodium ascorbate, and 
20 mM N-acetylglycine and monitored for O2 consumption.    
Reversibility of inactivation 
 An inactivation reaction of 250 µL containing 100 mM MES/NaOH pH 6.0, 30 mM 
NaCl, 1% (v/v) ethanol, 0.001% (v/v) Triton X-100, 10 µg/ml bovine catalase, 1.0 µM 
Cu(NO3)2, 5.0 mM sodium ascorbate, and 7 mM cinnamic acid was initiated by the addition of 
enzyme and incubated at 37 °C for 2 hours.  The reaction was then extensively dialyzed and 
concentrated to 50 µL.  The concentrate was then used to initiate a 1.0 mL reaction containing 
100 mM MES/NaOH pH 6.0, 30 mM NaCl, 1.0% (v/v) ethanol, 0.001% (v/v) Triton X-100, and 
10 mM hippurate. At various time intervals, a 100 µL aliquot was removed, added to a vial 
containing 20 µL of 6% (v/v) TFA to terminate the reaction, and the concentration of glyoxylate 
formed measured in the acidified samples to test for the recovery of activity. 
PAM labeling by dansyl-4-aminocinnamic acid 
 Covalent modification of PAM was investigated by using dansyl-4-aminocinnamic acid, 
a fluorescent molecule, as an inactivator. A 0.5 mL reaction containing 100 mM MES/NaOH pH 
6.0, 30 mM NaCl, 1% (v/v) ethanol, 0.001% (v/v) Triton X-100, 10 µg/ml bovine catalase, 1.0 
µM Cu(NO3)2, 5.0 mM sodium ascorbate, and 1.0 mM dansyl-4-aminocinnamic acid was 
initiated by the addition of 50 µg of enzyme and incubated at 37 °C for 3 hours.  The reaction 
mixture was dialyzed against 100 mL of 100 mM MES/NaOH pH 6.0, 30 mM NaCl, 1% (v/v) 
ethanol, and 0.001% (v/v) Triton X-100 for 4 hours changing the dialysis buffer every hour.  The 
reaction mixture was then concentrated by ultra-filtration to ~100 µL.  This sample was then 
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trypsin digested and the peptide fragments were analyzed by RP-HPLC utilizing a fluorescence 
detector.      
PAM labeling by 14C-cinnamic acid 
 Enzyme modification was also examined using radio-labeled cinnamic acid. A 250 µL 
reaction containing 100 mM MES/NaOH pH 6.0, 30 mM NaCl, 1% (v/v) ethanol, 0.001% (v/v) 
Triton X-100, 10 µg/ml bovine catalase, 1.0 µM Cu(NO3)2, 5.0 mM sodium ascorbate, and 3 µCi 
of 14C-cinnamic acid was initiated by the addition of 18 – 52 µg of PAM.  The reaction was 
allowed to incubate at 37 °C for 3 hours before ultra-filtration was performed.  The reaction was 
then washed with 200 µL of 100 mM MES/NaOH pH 6.0, 30 mM NaCl, 1% (v/v) ethanol, and 
0.001% (v/v) Triton X-100 and ultra-filtration repeated.  The underside of the filtration 
membrane was then washed with poly(ethylene glycol) to remove excess non-enzyme bound 
radio-labeled cinnamic acid.  Counts per minute were then compared using a scintillation 
counter. 
PAM modification through inactivation by cinnamic acid 
 Modification of the PAM active site by the reactive Cu/O species was also investigated as 
a possible means of cinnamic acid mediated inactivation.  A 100 µL reaction containing 100 mM 
MES/NaOH pH 6.0, 30 mM NaCl, 1% (v/v) ethanol, 0.001% (v/v) Triton X-100, 1.0 µM 
Cu(NO3)2, 5.0 mM sodium ascorbate, and 3 mM cinnamic acid was initiated with 20 µg of PAM 
and incubated at 37 °C for 12 hours.  The enzyme was then dialyzed against 100 mM 
MES/NaOH pH 6.0, 30 mM NaCl, 1% (v/v) ethanol, 0.001% (v/v) Triton X-100 for 4 hours and 
the volume reduced to ~40 µL by ultra-filtration.  The enzyme was then analyzed by MALDI-
TOF against control for any modification.  The reaction was then repeated as previously stated 
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followed by trypsin digestion.  The reaction was then analyzed by LC/MS, LC/MS/MS, and 
MALDI-TOF. 
PAL inactivation assay 
To determine if the cinnamic acid was also inactivating PAL activity by PAM, initial rates of 
glyoxylate formation from α-hydroxyhippurate, a known PAL substrate, were monitored.  
Reactions of 20 µg of PAM in a 100 µL solution containing 100 mM MES/NaOH pH 6.0, 30 
mM NaCl, 1.0% (v/v) ethanol, 0.001% (v/v) Triton X-100, and a concentration of cinnamic acid 
or analog equal to 5-times KI of PHM-related inhibition for that particular inhibitor were 
incubated for 2 hours.  A 20 µL aliquot was removed and used to initiate a 1.0 mL reaction 
containing 100 mM MES/NaOH pH 6.0, 30 mM NaCl, 1.0% (v/v) ethanol, 0.001% (v/v) Triton 
X-100, and 10 mM α-hydroxyhippurate. At 10 minute intervals from 10 to 60 min., a 100 µL 
aliquot was removed, added to a vial containing 20 µL of 6% (v/v) TFA to terminate the 
reaction, and the concentration of glyoxylate formed measured in the acidified samples. 
Glyoxylate was determined by the spectrophotometric method of Christman et al. [23] as 
modified by Katopodis and May [24].  Standard curves of [glyoxylate] vs. A520 were constructed 
in the appropriate buffers using a glyoxylate solution that had been calibrated by measuring the 
glyoxylate-dependent oxidation of NADH (∆ε340 = 6.22 x 10
3
 M
-1
 cm
-1
) as catalyzed by lactate 
dehydrogenase.   
Analysis of steady-state kinetic data 
 Initial rate studies that resulted in competitive inhibition were also analyzed by 
Kaleidagraph® fit of v vs. [S] as a function of inhibitor concentration to equation 1.   
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                       (1) 
Where KM,app is the apparent Michaelis constant for the oxidizable substrate at fixed [ascorbate] 
and ambient [O2] concentrations and VMAX,app is the apparent maximum initial velocity at 
saturating [S].   
 Inactivation kinetics were analyzed by Kaleidagraph® fit of 1/kobs vs 1/[ I ] to equation 2.  
                                              (2) 
Where kobs is the observed rate of inactivation, and kinact is the intrinsic rate of inactivation of 
enzyme. 
Results 
Cinnamic acid and analogs as inhibitors of PAM 
 Cinnamic acid and several analogs were initially investigated as small molecule 
inhibitors of PAM.  Cinnamic acid was shown to inhibit the consumption of O2 from N-
acetylglycine in a competitive manner (Figure 3.3) yielding the steady-state kinetic values as 
described by equation 1 (Table 3.1).  All cinnamic acid analogs were assumed competitive and 
also analyzed according to equation 1.  
Inactivation of PAM by cinnamic acid  
 Cinnamic acid was investigated as an inactivator of PAM by the dilution method, a 
common method for determining the kinetic parameters of time-dependent inactivators [25].  
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Inactivation experiments performed with cinnamic acid indicated that it is a time-dependent 
inactivator of PAM (Figure 3.4).  The inactivation was pseudo first-order and concentration 
dependent, as well as O2- and ascorbate-dependent (Figure 3.5).  Substrate was also found to 
protect against inactivation of PAM by cinnamic acid.  Perdeuterated cinnamic acid was also 
investigated in search of an isotope effect on kinact as evidence for H-abstraction, though one was 
not observed (Table 3.2).   
Inactivation of PAL activity 
 Cinnamic acid and analogs were tested as PAL inactivators as well to investigate whether 
or not the PAM activation occurring was specific to the PHM domain.  The experiment indicates 
that PAL is completely unaffected by cinnamic acid and the various analogs tested and retained 
100% activity when compared to the control reaction (Figure 3.6).   
Irreversible inactivation 
 Cinnamic acid was able to irreversibly inactivate PAM.  Extensive dialysis of a reaction 
mixture incubated with cinnamic acid yielded dead enzyme incapable of producing glyoxylate 
from hippuric acid (Figure 3.7).   
Non-labeled PAM 
 Multiple experiments were performed in an attempt to verify covalent linkage of 
cinnamic acid to PAM.  Both the fluorescent labeling with dansyl-4-aminocinnamic acid, and the 
radio labeling experiments indicated that cinnamic acid was not covalently linking to the 
enzyme.  Multiple methods of mass analysis were performed in an attempt to elucidate any auto-
oxidation or hydroxylation of the PAM active site as has been hypothesized in earlier studies 
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with 4-phenyl-3-butenoic acid [26].  However, we were unable to detect any modification of the 
enzyme after exhausting all efforts and resources (Figure 3.8).   
Docking of cinnamic acid and analogs 
 Docking of the investigated compounds yielded poses in agreement with the competitive 
nature of inhibition observed experimentally.  The compounds bind forming a salt bridge 
between the carboxy terminus and the guanidino group of R240 as has been previously shown 
with glycine-extended substrates [27].  This interaction aligns the Cα-H in close proximity to 
CuM (Figure 3.9).  However, the lack of glycyl amide hydrogen to H-bond with the N316 oxygen 
coupled with the compounds’ small size preventing any interaction with the nearby hydrophobic 
pocket would allow for a great deal of movement within the active site making hydrogen 
abstraction difficult. 
Computation results for bond energy 
 The ab initio calculations performed to estimate the bond dissociation energies of the Cα-
H bond for cinnamic acid and the investigated analogs indicate that more than 110 kcal/mol are 
needed (Table 3.3).     
Discussion 
 Cinnamic acid is a structural analogue of 4-phenyl-3-butenoic acid (PBA), a well-
documented mechanism-based, irreversible inhibitor (inactivator) of the PHM domain as both 
molecules contain an olefin moiety [16, 24].  While PBA has been suggested to be hydroxylated 
at bo th the α and  γ p osition s b y PHM [26], none of the compounds tested within this study 
displayed oxygen consumption when screened for activity even though inactivation was O2- and 
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ascorbate-dependent.  Further evidence that hydroxylation was absent with cinnamic acid was 
the lack of a deuterium kinetic isotope effect for kinact or kinact/KI.  Although the presence of an 
isotope effect would give evidence for hydrogen abstraction from the Cα of cinnamic acid, 
absence may suggest that the magnitude of Dkinact may be suppressed by much faster steps in the 
mechanism.  The lack of PHM inactivation with 3-phenyloxirane-2-carboxylic acid suggests that 
C-H cleavage is required to generate the inactivating olefin intermediate species in the 
hydroxylation pathway.  The C-H bond dissociation energies, displayed in Table 3.3, display 
enthalpies for each conjugated species to be very close to each other (a difference of only 13 
kcal/mole).  Therefore, if the inactivation species were ultimately dependent only on a C-H 
cleavage step, 3-phenyloxirane-2-carboxylic acid would be expected to inactivate PHM.  This 
suggests that the inactivation is dependent on the presence of an olefin while the lack of 
inactivation by phenylpropiolic acid, the alkyne derivative, suggests that the Cα-H is also a 
prerequisite for inactivation.  This may suggest that the inactivating species is an intermediate 
along the hydroxylation pathway after the abstraction of the Cα-H and that the inactivation is 
dependent on the olefin.  This species may be a vinyl radical present on the Cα as this radical 
would not delocalize. 
 The instrumental nature of the olefin radical generated upon hydrogen abstraction further 
suggest that dynamical freedom of this small inactivator may also be important to this 
inactivation mechanism.  The modeling performed suggests that there are few interactions to 
hold cinnamic acid in the active site other than the salt-bridge with R240.  This is also reflected 
in the poor KI value for cinnamic acid (3.6 mM, Table 1).  This may be directly attributed to the 
lack of amide hydrogen to anchor the Cα-H and properly position it for abstraction along with 
the inability of the phenyl ring to bury itself into the hydrophobic pocket to further stabilize the 
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molecule. This results in a significant increase in the conformational sampling and a decrease in 
the probability of proper wave function overlap between donor and acceptor [28].  Upon 
successful hydrogen abstraction, the radical character generated can be shared between α and β 
carbons.  Assuming the Cu-alkoxide intermediate, hydroxylation of such a mobile species with 
delocalized radical character would prove difficult.  Thus, the reactive cinnamic acid species 
may leave the active site allowing for hydroxylation to occur by the addition of water to the 
radical intermediate.  This would leave the activated Cu-oxo species to either modify the enzyme 
in a way undetectable by mass analysis or perhaps linger in a trapped dynamic state unable to 
return to the free-enzyme state (Figure 3.10).  
Conclusion 
 In conclusion, we have demonstrated that potential diabetes drug candidates are capable 
of PAM inactivation.  Because of the importance of PAM in the biosynthesis of amidated peptide 
hormones, these results are of great pharmacological significance.  As the development of small-
molecule insulin secretion drugs with the α,β olefin moiety progresses, special attention must be 
paid to the possible inactivation of PAM.  These findings are also therapeutically relevant as 
PAM is over-expressed in both small cell lung cancer and prostate cancer [29-31] making it a 
possible drug target.   
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Figure 3.1. PAM catalytic scheme.   
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Figure 3.2. Illustration of carbon-hydrogen bond elongation for the DFT calculation of 
bond dissociation energies. 
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Figure 3.3. Inhibition of PAM by cinnamic acid.  Initial rates were determined at 37 ◦C as 
described in the Materials and Methods section.  The points are experimentally determined 
initial rates.  The lines were computer fit to the data using equation 1. 
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Figure 3.4. Inactivation plots for cinnamic acid.  Experiments were performed as indicated 
in the Materials and Methods section and analyzed as indicated in the analysis subsection. 
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Figure 3.5. Ascorbate and O2 dependence of PHM inactivation investigated by oxygen 
consumption as described in the Materials and Methods section. 
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Figure 3.6. Cinnamate analogs as inactivators of the PAL activity of PAM by the glyoxylate 
assay.  
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Figure 3.7. Reversibility of inactivation of PAM by cinnamic acid. 
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Figure 3.8. MALDI-TOF overlay of Trypson-digested active (blue) and cinnamate-
inactivated (green) PAM. 
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Figure 3.9. Cinnamate docked in the active site of the PHM crystal structure (1SDW). 
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Figure 3.10. Postulated cinnamate inactivation schemes where cinnamate radical is 
released prior to hydroxylation leaving the activated Cu-alkoxide species and where 
activated Cu/O species is unable to abstract Cα-H atom.   
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List of Tables 
Table 3.1. Inhibition constants calculated from computer fit of data to equation 1. 
Structure Name KI (mM) 
O
HO
 
Cinnamic acid 3.5 ± 0.2 
O
HO F3C
 
2-trifluorocinnamic acid 0.22 ± 0.02 
O
HO
NO2
 
4-nitrocinnamic acid 0.56 ± 0.04 
O
OH
ON
H  
4-anilino-4-oxobut-2-enoic acid 3.5 ± 0.3 
O
HO
N  
3-(3-pyridyl)acrylic acid 5.9 ± 0.6 
O
OH 
Phenylpropiolic acid 2.4 ± 0.3 
O
OH
O
O
 
 
3.4-methylenedioxycinnamic acid 0.28 ± 0.04 
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O
HO
N
 
N,N-dimethylaminocinnamic acid 3.1 ± 0.5 
O
OHO
NH2
 
Maleamic acid 0.89 ± 0.13 
O
OH
ON
H
 
N-phenylmaleamic acid 1.7 ± 0.2 
N
NH
O
HO
 
Urocanic acid 10.5 ± 1.6 
O
O
HO
 
3-phenyloxirane-2-carboxylic acid 1.6 ± 0.1 
O
HO
NH2
 
4-aminocinnamic acid 0.54 ± 0.06 
O
HO
NH
S
N
O O
 
Dansyl-4-aminocinnamic acid 0.011 ± 0.001 
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Perdeuterated cinnamic acid 3.5 ± 0.3 
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Table 3.2.  Inactivation constants calculated by Kitz-Wilson analysis using the dilution assay 
method as outline in the materials and methods section. 
Compound kinact (min-1) kinact/KI (mM-1 min-1) 
Cinnamic acid 0.15 ± 0.02 0.04 ± 0.006 
N,N-dimethylaminocinnamic acid 0.08 ± 0.01 0.03 ± 0.005 
4-aminocinnamic acid 0.03 ± 0.005 0.06 ± 0.01 
Dansyl-4-aminocinnamic acid 0.21 ± 0.03 19.1 ± 3.2 
Perdeuterated cinnamic acid 0.15 ± 0.01 0.04 ± 0.004 
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Table 3.3.  Calculated bond dissociation energies of selected cinnamate analogs by DFT/6-31G*. 
Structure Name kcal/mol 
O
HO
 
Cinnamic acid 114 
O
HO
NH
S
N
O O
 
Dns-4-aminocinnamic acid 116 
O
O
HO
 
3-phenyloxirane-2-carboxylic acid 117 
O
HO
NH2
 
4-aminocinnamic acid 123 
O
HO
NO2
 
4-nitrocinnamic acid 127 
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Introduction 
 Peptidylglycine α-amidating monooxygenase (PAM) is a bifunctional metalloenzyme 
responsible for the conversion of glycine-extended peptide prohormones to the active hormone, 
peptide-amide [1, 2].  Catalysis proceeds through the abstraction of the glycyl Cα hydrogen via a 
reactive Cu-oxo species followed by hydroxylation, and finally the cleavage of the N-Cα bond to 
yield glyoxylate and the peptide-amide.  Two domains in PAM are responsible for this 
chemistry.  The peptidylglycine α-hydroxylating monooxygenase (PHM) domain is responsible 
for the hydrogen abstraction and subsequent hydroxylation while the peptidylglycine 
amidoglycolate lyase (PAL) domain is responsible for the cleavage of the N-Cα bond (Figure 
4.1) [3].  PHM activity is copper-, ascorbate-, and O2-dependent while PAL catalysis is zinc-, 
calcium-, and iron-dependent [4-9].   
 PHM and its sister enzyme dopamine β-monooxygenase (DβM) are mechanistically 
related.  Both PHM and DβM produce essential signaling molecules which are stored in 
secretory granules and used for intercellular communication [10].  They catalyze very similar 
reactions utilizing a reactive copper-oxygen species to hydroxylate their very different respective 
substrates (Figure 4.2).  PHM and DβM are essential enzymes as genetically engineered mice 
and Drosophila melanogaster lacking a functional PHM or DβM gene generally die as embryos 
[11-13].  PAM/PHM and DβM have been the focus of much mechanistic study.  Many of the 
proposed mechanistic schemes involve a substrate free radical intermediate (Figure 4.3).  All of 
the work providing evidence for this radical intermediate has been performed on DβM.  Several 
studies in particular have provided evidence for a substrate radical mechanism in DβM [14-17].  
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No su ch  stu dies have been  p erformed  with PHM thou g h the results of the DβM stu d ies have 
been applied towards the elucidation of both mechanisms.   
 Here we report experiments that provide evidence for a radical intermediate in PAM 
catalysis.  Ring-substituted suicide substrates are used to probe electronic effects to define the 
nature of the reactive intermediate.  The results provide evidence for a radical mechanism and 
are in agreement with previous studies performed on DβM.  
Materials and Methods 
Materials 
 4-Phenyl-3-butenoic acid and N-acetylglycine were from Sigma Aldrich.  4-(4-
chlorophenyl)-3-butenoic acid, 4-(4-methoxyphenyl)-3-butenoic acid, 4-(3-chlorophenyl)-3-
butenoic acid, and 4-(3-methoxyphenyl)-3-butenoic acid were a gift from Dr. John Vederas.  
Bovine catalase was from Worthington.  Recombinant rat PAM was a gift from Unigene 
Laboratories, Inc.  All other reagents were of the highest quality commercially available. 
In silico docking 
 The crystal structure for reduced peptidylglycine α-hydroxylating monooxygenase 
(PHM) was obtained from the Protein Data Bank (http://www.rcsb.org/pdb/, 1SDW) [18].  All 
species deemed superfluous for ligand binding were removed from the pdb file (nickel, water, 
glycerol, and substrate).  Formal charges for enzyme-bound copper ions were set as 1, bond 
orders were corrected, and hydrogens were added using Maestro (www.schrodinger.com).  
Further receptor refinements were carried out utilizing ProteinPrep from within Maestro.  
Investigation of the phenylbutenoate binding modes were performed using Glide[19] and 
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Qsite[20] jointly for quantum polarized ligand docking.  This method generates highly accurate 
binding modes by quantum mechanically calculating the partial atomic charges of the docked 
ligand using B3LYP/6-31G* within the receptor and subsequently re-docking the ligand [21, 22].   
Radical stabilization energies 
 To investigate the effects of the substituents on the relative stability of the Cα radical, ab 
initio molecular orbital theory and density functional theory calculations were performed using 
PCGAMESS.  The geometries of each phenylbutenoate and the corresponding radical along with 
methane and the methane radical were determined at the B3LYP/6-31G(d) level.  Single point 
energy calculations were then carried out on the optimized structures at the MP2 level with 6-
311+G(2df,p) basis sets. Radical stabilization energies of PBA radicals were calculated as 
energies of the following reaction: 
                                     (1) 
Thus, the difference between the C—H bond dissociation energy of methane and the C—H bond 
dissociation energy in the phenylbutenoates.   
                             (2) 
A positive radical stabilization energy value would then indicate that the radical is stable relative 
to the methane radical compared with the corresponding closed-shell systems.   
Inactivation of PAM by 4-phenyl-3-butenoates at ambient O2 
 Inactivation reactions of 50 µL containing 100 mM MES/NaOH pH 6.0, 30 mM NaCl, 
1% (v/v) ethanol, 0.001% (v/v) Triton X-100, 10 µg/ml bovine catalase, 1.0 µM Cu(NO3)2, 5.0 
mM sodium ascorbate, and various concentrations of phenylbutenoates were initiated by the 
addition of enzyme and incubated at 37 °C.  Aliquots of 20 µL were withdrawn at various 
intervals and diluted into 2.0 mL reactions containing 100 mM MES/NaOH pH 6.0, 30 mM 
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NaCl, 1% (v/v) ethanol, 0.001% (v/v) Triton X-100, 10 µg/ml bovine catalase, 1.0 µM 
Cu(NO3)2, 5.0 mM sodium ascorbate, and 20 mM N-acetylglycine.  The residual activity was 
thus measured by the rate of oxygen consumption.  Because of the high potency of the 
phenylbutenoates, the inactivation reactions were not performed continuously due to the down 
time required to prepare the next reaction mixture within the oxygen electrode chamber.  Thus, a 
separate reaction was required for each time-point at each concentration.   
Inactivation of PAM by 4-phenyl-3-butenoates at variable O2 concentrations 
 Inactivation stock reactions of 200 µL containing 100 mM MES/NaOH pH 6.0, 30 mM 
NaCl, 1% (v/v) ethanol, 0.001% (v/v) Triton X-100, 10 µg/ml bovine catalase, 1.0 µM 
Cu(NO3)2, 5.0 mM sodium ascorbate, and various concentrations of phenylbutenoates were 
incubated at 37 °C for 10 minutes in septum sealed tubes.  The rubber septum was then pierced 
with a 25 gauge needle as a pressure release and a second needle attached to non-permeable 
rubber tubing.  Through this tubing, the desired concentration of O2 was delivered by means of 
an ACS certified O2:N2 mixture.  The delivery needle was submerged in the reaction solution to 
“bubble through” the gas mixture.  Bubbling of the gas mixture through the reaction solution 
prevented the evaporation of reaction mixture that was noted when blowing over the gas mixture 
while stirring the solution.  While the total volume change related to this evaporation was small 
in absolute terms (20 – 40 µL), it was significant relative to the total reaction volume making the 
inactivator concentrations unreliable.  The thin gauge needle allowed for sufficient aeration of 
the samples providing both accurate concentrations of O2.  After streaming the gas mixture 
through the reaction sample for 5 minutes, one empty reaction tube was prepared with rubber 
septum for each time point to be taken at that particular inactivator concentration.  A typical 
inactivation study by the dilution method is classically a continuous assay.  However, the time 
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required to prepare the oxygen electrode in between time points rendered a continuous assay 
method impossible.  Thus, each time point required the preparation of a new reaction mixture 
and the incubation was repeated from time = 0.  Each empty reaction tube with septum was then 
purged with the desired O2:N2 reaction mixture and the needles removed.  30 µL of the stock 
reaction was then placed into each purged tube with a 25 gauge needle and syringe.  Each 
reaction was then initiated with enzyme and incubated for the desired length of time before 
removing a 20 µL aliquot and initiating a 2.0 mL reaction containing 100 mM MES/NaOH pH 
6.0, 30 mM NaCl, 1% (v/v) ethanol, 0.001% (v/v) Triton X-100, 10 µg/ml bovine catalase, 1.0 
µM Cu(NO3)2, 5.0 mM sodium ascorbate, and 20 mM N-acetylglycine and monitoring O2 
consumption to examine residual enzyme activity. 
Reversibility of Inactivation 
 An inactivation reaction of 100 µL containing 100 mM MES/NaOH pH 6.0, 30 mM 
NaCl, 1% (v/v) ethanol, 0.001% (v/v) Triton X-100, 10 µg/ml bovine catalase, 1.0 µM 
Cu(NO3)2, 5.0 mM sodium ascorbate, and 100 µM 4-phenyl-3-butenoic acid was initiated by the 
addition of enzyme and incubated at 37 °C for 2 hours.  The reaction was then extensively 
dialyzed and concentrated to ~50 µL.  The concentrate was then used to initiate a 1.0 mL 
reaction containing 100 mM MES/NaOH pH 6.0, 30 mM NaCl, 1.0% (v/v) ethanol, 0.001% 
(v/v) Triton X-100, and 10 mM hippurate. At various time intervals, a 100 µL aliquot was 
removed, added to a vial containing 20 µL of 6% (v/v) TFA to terminate the reaction, and the 
concentration of glyoxylate formed measured in the acidified samples to test for the recovery of 
activity. 
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Inactivation of PAL activity by 4-phenyl-3-butenoic acid 
 To determine if 4-phenyl-3-butenoic acid was also inactivating PAL activity of PAM, 
initial rates of glyoxylate formation from α-hydroxyhippurate, a known PAL substrate, were 
monitored.  Reactions of 20 µg of PAM in a 100 µL solution containing 100 mM MES/NaOH 
pH 6.0, 30 mM NaCl, 1.0% (v/v) ethanol, 0.001% (v/v) Triton X-100, and 100 µM 4-phenyl-3-
butenoic acid was incubated for 2 hours.  A 20 µL aliquot was removed and used to initiate a 1.0 
mL reaction containing 100 mM MES/NaOH pH 6.0, 30 mM NaCl, 1.0% (v/v) ethanol, 0.001% 
(v/v) Triton X-100, and 10 mM α-hydroxyhippurate. At various time intervals, a 100 µL aliquot 
was removed, added to a vial containing 20 µL of 6% (v/v) TFA to terminate the reaction, and 
the concentration of glyoxylate formed measured in the acidified samples. 
Determination of partition ratios 
 To determine the partition ratio for product formation versus enzyme inactivation, a 2.0 
mL reaction containing 100 mM MES/NaOH pH 6.0, 30 mM NaCl, 1% (v/v) ethanol, 0.001% 
(v/v) Triton X-100, 10 µg/ml bovine catalase, 1.0 µM Cu(NO3)2, 5.0 mM sodium ascorbate, and 
1 mM of the desired 4-phenyl-3-butenoic acid derivative.  Oxygen consumption was then 
monitored by oxygen electrode to monitor hydroxylation activity.   
Determination of glyoxylate concentration 
 Glyoxylate was determined by the spectrophotometric method of Christman et al. [23] as 
modified by Katopodis and May [24].  Standard curves of [glyoxylate] vs. A520 were constructed 
in the appropriate buffers using a glyoxylate solution that had been calibrated by measuring the 
glyoxylate-dependent oxidation of NADH (∆ε340 = 6.22 x 10
3
 M
-1
 cm
-1
) as catalyzed by lactate 
dehydrogenase. 
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Investigation of inactivation through PAM modification 
 Modification of the PAM active site by the activated Cu/O species was investigated as a 
possible means of phenylbutenoate mediated inactivation in addition to covalent labeling by 
phenylbutenoate.  A 100 µL reaction containing 100 mM MES/NaOH pH 6.0, 30 mM NaCl, 1% 
(v/v) ethanol, 0.001% (v/v) Triton X-100, 1.0 µM Cu(NO3)2, 5.0 mM sodium ascorbate, and 500 
µM 4-phenyl-3-butenoic acid was initiated with 20 µg of PAM and incubated at 37 °C for 12 
hours.  The enzyme was then dialyzed against 100 mM MES/NaOH pH 6.0, 30 mM NaCl, 1% 
(v/v) ethanol, 0.001% (v/v) Triton X-100 for 4 hours and the volume reduced to ~40 µL by ultra-
filtration.  The enzyme was then analyzed by MALDI-TOF against control for any modification.  
The reaction was then repeated as previously stated followed by trypsin digestion.  The reaction 
was then analyzed by both LC/MS and MALDI-TOF. 
Analysis of kinetic data 
 Inactivation kinetics were analyzed by Kaleidagraph fit of 1/kobs vs 1/[ I ] to equation 3.  
                                               (3) 
where kobs is the observed rate of inactivation, and kinact is the intrinsic rate of inactivation of 
enzyme. 
Results 
Molecular modeling 
 The phenylbutenoates of interest were docked into the reduced PHM crystal structure.  
As expected, the terminal carboxylate formed a salt-bridge with R240 (Figure 4.4).  The Cα-H is 
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in close proximity to the catalytic active site copper, CuM (Figure 4.5).  The phenylbutenoates are 
not large enough, however, for the phenyl groups to bury themselves into the hydrophobic 
pocket to restrict movement of the molecule.  The small size in addition to the lack of an amide 
hydrogen needed for hydrogen bonding to N316 to further limit ligand mobility within the active 
site allows for a great deal of movement of the phenylbutenoates once within the active site.  
Molecular dynamics simulations performed with the docked 4-phenyl-3-butenoate using NAMD 
2.6 demonstrate that there is, indeed, a great deal of mobility for these small compounds without 
the requisite interactions present when peptide-gly substrates are bound to PAM. 
Partition ratios 
 The partition ratios for the ring-substituted phenylbutenoates were determined by 
measuring the total oxygen consumed during inactivation as a stoichiometric amount is O2 is 
consumed during hydroxylation.  Thus, upon complete inactivation the amount of O2 consumed 
is equivalent to the amount of hydroxylated phenylbutenoate produced.  All phenylbutenoates 
investigated are efficient inactivators with the most efficient giving a partition ratio of 18 
turnovers per inactivation (Table 4.1).   
Inactivation of PAM by phenylbutenoates  
 Several ring-substituted phenylbutenoates were investigated as inactivators of PAM by 
the dilution method, a common method for determining the kinetic parameters of time-dependent 
inactivators [25].  Inactivation experiments performed with these analogs indicated that they are 
indeed time-dependent inactivators of PAM (Figure 4.6).  The inactivation was pseudo first-
order and concentration dependent, as well as O2- and ascorbate-dependent.  Substrate was found 
to protect against inactivation of PAM by 4-phenyl-3-butenoic acid (Figure 4.7).  The 
inactivation was found to be irreversible.  Extensive dialysis of a reaction mixture incubated with 
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4-phenyl-3-butenoic acid yielded dead enzyme incapable of producing glyoxylate from hippuric 
acid and no oxygen consumption was observed when monitored with the oxygen electrode.  The 
kinetic parameters for inactivation under ambient conditions are listed in Table 4.2.   
 The ring-substituted phenylbutenoates were then further examined to investigate the 
effects of substitution on the partition ratio, Vmax/kinact, and the kinetics of inactivation.  A double 
reciprocal plot of 1/kobs vs. 1/[PBA] at fixed O2 concentrations yields a pattern of intersecting 
lines  
       (3) 
with a slope of: 
                                                        (4) 
and the ordinate intercept of: 
                                                         (5) 
A replot of the intercept vs. 1/[O2] yields a straight line.  From the inactivation kinetics at 
varying concentrations of O2, a linear free energy plot of  values can be constructed as 
a function of electron-withdrawing or electron-donating ability of the substituent (Figure 4.8).   
Inactivation of PAL activity 
 4-Phenyl-3-butenoic acid was tested as a PAL inactivator as well to investigate whether 
or not the PAM inactivation occurring was specific to the PHM domain.  Glyoxylate was readily 
formed from α-hydroxyhippurate, a known PAL substrate.  The experiment indicates that PAL is 
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completely unaffected by 4-phenyl-3-butenoic acid and retained 100% activity when compared 
to the control reaction (Figure 4.9).   
Non-labeled PAM 
 Multiple methods of mass analysis were performed in an attempt to elucidate any auto-
oxidation or hydroxylation of the PAM active site as has been hypothesized in earlier studies 
with 4-phenyl-3-butenoic acid [26].  While the hydroxylated product was detected by LC/MS, 
we were unable to detect any modification of the enzyme by MALDI-TOF, or LC/MS and 
LC/MS/MS on trypsin digested samples (Figure 4.10).   
Radical stabilization energies 
 The radical stabilization energies calculated from the isodesmic reaction discussed 
previously indicate that several of the phenylbutenoates are capable of forming extremely stable 
radicals when compared to the methane radical [27].  While the radical stabilities are relative and 
not absolute, the data indicates that the 4-(4-chlorophenyl)-3-butenoic acid and 4-(4-
methoxyphenyl)-3-butenoic acid derivatives are greater than an order of magnitude more stable 
than the other phenylbutenoates analogs investigated (Table 4.3).  These two very stable 
derivatives also had the highest partition ratios.  Thus, there exists a direct correlation between 
radical stability and the ability of PHM to hydroxylate the phenylbutenoates after hydrogen 
abstraction. 
Discussion 
 The phenylbutenoates investigated meet the criteria for mechanism-based inhibitors of 
PAM.  The inactivation is both ascorbate- and O2- dependent.  The phenylbutenoates all act as 
suicide substrates under turnover conditions inactivating the enzyme.  The inactivation is 
protected against by the presence of substrate. 
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 The experiments performed were designed to give evidence of a radical intermediate 
being formed during PAM catalysis.  To accomplish this, the kinetics of inactivation and the 
partition ratios were examined using phenylbutenoates with substituents on the phenyl ring of 
different electron-donating and electron-withdrawing effects.  The steady-state kinetics of PAM 
with PBA can be described as 
 
 
A minimal mechanism accounting for catalysis and inactivation is described as 
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For this inactivation scheme, the rate constant for the catalytic steps is k9.  is then the 
kinetic parameter that contains the catalytic step and would equal .  The partition 
ratio for inactivation for a mechanism-based inhibitor is .  Thus, one can arrive at 
 by simply multiplying the partition ratio by the inactivation kinetic data; this allows the 
attainment of steady-state kinetic data when such data cannot be obtained directly.  Therefore, 
we have multiplied the partition ratios by the respective  values of the 
phenylbutenoates to calculate the  values.  A free energy plot was then created with these 
values and compared to various sigma constants for each substituent (Figure 4.11).  The different 
sigma constants differ in that they are based on different standard reaction series.  When 
compared to σ+, a ρ value of -1.03 was obtained. 
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 Similar studies have previously been performed on D-amino acid oxidase.  This 
flavoprotein was found to go through a carbanion intermediate [28].  The ρ value obtained when 
Vmax was measured for a series of ring-substituted phenylglycines was 5.44 [29].  This finding 
suggests that PAM does not proceed through a carbanion mechanism.  That PAM proceeds via a 
radical mechanism is consistent with the data which shows a small absolute magnitude for the 
valu e of ρ and  also the correlation with σ+, results characteristic of a radical mechanism [14].  
Studies on styrene derivatives involving allylic hydrogen abstraction through a radical 
mechanism have demonstrated similar results, finding a Hammett slope ρ = -0.82 [30].   
 The partition ratios and relative radical stabilities calculated using ab initio methods also 
support a radical mechanism.  The partition ratios are all within an order of magnitude.  The 
agreement seen between the radical stability of the two most stable phenylbutenoates calculated 
and that they are also the two ligands with the highest partition ratios provides further evidence 
that catalysis proceeds via a radical mechanism.  The increased stability for the radical on the Cα 
allows for a greater ease in hydroxylation by the PHM domain in PAM.  This leads to more 
turnovers before inactivation occurs.   
Conclusion 
 In conclusion, we report here findings that suggest PAM catalysis occurs through a 
radical mechanism.  Other studies have shown that two hydroxylation products are formed 
during phenylbutenoate catalysis leading to both the alpha and gamma hydroxylated derivatives 
[26].  The most likely mechanism by which this hydroxylation may proceed is through the 
resonance of a radical generated at the alpha position during hydrogen abstraction (Figure 4.12).  
The dynamical freedom allowed the phenylbutenoate from the lack of amide-hydrogen to N316 
hydrogen bonding, an interaction present in the peptide-gly substrates (Figure 4.13), has been 
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hypothesized to cause the lack of absolute stereospecificity in hydroxylation of the 2-position 
observed in earlier studies [26].  This mobility coupled with the resonance of the radical may 
reduce the probability of hydroxylation at the 2-position allowing for release of the PBA radical 
intermediate leaving an activated oxygen at CuM.  This would also allow for autoxidation of the 
active site resulting in inactive enzyme.  Water would then be the hydroxylating species for the 
4-OH-PBA species. 
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List of Figures 
 
Figure 4.1. The reactions catalyzed by PHM and PAL.  Bifunctional PAM is compromised 
of the two monofunctional enzymes.  
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Figure 4.2. The reaction schemes of PHM (left) and DβM (right). 
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Figure 4.3. The hydrogen abstraction mechanisms for the two most accepted mechanisms 
of PHM and DβM abstraction and hydroxylation.  Mechanism A has been proposed by 
Klinman while mechanism B has been proposed by Chen et al. 
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Figure 4.4. 4-phenyl-3-butenoate forming a salt bridge with the guanidino group of R240.  
The secondary structure is rendered as a transparent ribbon in orange.  Note that carbon is 
teal, nitrogen is blue, oxygen is red, and hydrogen is white. 
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Figure 4.5. 4-phenyl-3-butenoate shown docked within the PHM active site showing the 
proximity of the Cα-H to the CuM.  A lack of interaction with N316 should also be noted.  
Note that carbon is teal, nitrogen is blue, oxygen is red, sulfur is yellow, hydrogen is white, 
and copper is orange.   
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Figure 4.6. The time-dependent inactivation of PHM activity by 4-(3-chlorophenyl)-3-
butenoic acid.   
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Figure 4.7. Substrate was shown to protect against inactivation by 4-phenyl-3-butenoic 
acid. 
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Figure 4.8. Linear free energy plot of kinact/KO2 values as a function of electron-withdrawing 
or electron-donating ability of the substituent. 
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Figure 4.9. The effect of 4-phenyl-3-butenoic acid on the PAL activity of PAM.  
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Figure 4.10. The trypsin digested MALDI-TOF fingerprint of normal (blue) and 4-phenyl-
3-butenoic acid inactivated (green) PAM. 
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Figure 4.11. Free energy plot of Vmax/KO2 as a function of electron-withdrawing and 
electron-donating ability of the substituent. 
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Figure 4.12. Radical rearrangement between alpha and gamma positions in 4-phenyl-3-
butenoic acid leading to two hydroxylated products. 
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Figure 4.13. Benzylglycine docked to illustrate the proper hydrogen bonding interaction 
between N316 and the amide-hydrogen of the substrate.   
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Tables 
Table 4.1. Partition ratios for ring-substituted 4-phenyl-3-butenoic acids 
Name Partition Ratio 
4-phenyl-3-butenoic acid 85 
4-(4-chlorophenyl)-3-butenoic acid 94 
4-(3-chlorophenyl)-3-butenoic acid 35 
4-(4-methoxyphenyl)-3-butenoic acid 143 
4-(3-methoxyphenyl)-3-butenoic acid 18 
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Table 4.2. The kinetic parameters for the inactivation of PHM by ring-substituted 4-phenyl-3-
butenoic acids. 
Name kinact (min-1) KI (mM) 
4-phenyl-3-butenoic acid 4.18 0.004 
4-(4-chlorophenyl)-3-butenoic acid 13.6 0.98 
4-(3-chlorophenyl)-3-butenoic acid 1.18 1.45 
4-(4-methoxyphenyl)-3-butenoic acid 0.22 0.06 
4-(3-methoxyphenyl)-3-butenoic acid 0.10 0.04 
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Table 4.3.  Radical stabilization energies for ring-substituted 4-phenyl-3-butenoic acids. 
Name RSE (kcal/mol) 
4-phenyl-3-butenoic acid 47.6 
4-(4-chlorophenyl)-3-butenoic acid 1480 
4-(3-chlorophenyl)-3-butenoic acid 53.9 
4-(4-methoxyphenyl)-3-butenoic acid 1440 
4-(3-methoxyphenyl)-3-butenoic acid 49.5 
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Introduction 
Peptidylglycine α-amidating monooxygenase (PAM) is a copper- and zinc-dependent, 
bifunctional enzyme that catalyzes the cleavage of glycine-extended peptides to the 
corresponding amides and glyoxylate[1, 2].  The sequential action of hydroxylating the glycyl α-
carbon and then cleaving the carbon-amide bond are dependent upon the peptidylglycine α-
hydroxylating monooxygenase (PHM) and peptidylglycine amidoglycolate lyase (PAL) 
domains, respectively (Figure 5.1) [3-11].  
PAM is responsible for activating peptide prohormones in vivo.  Although a considerable 
body of mechanistic and structure/function data has been generated in an attempt to understand 
this redox chemistry [12-17], there are still crucial unanswered questions regarding electron 
transfer, dioxygen activation, and radical formation during C-H bond cleavage that preclude a 
comprehensive understanding of glycine hydroxylation.  Crystallographers have stated that the 
reduction of PAM by ascorbate is collisional as they have been unable to identify a binding site 
for ascorbate.  Mimosine, however, has been shown to be a competitive inhibitor against 
ascorbate suggesting that a binding site must exist [18].   
This work attempts to elucidate possible binding sites for ascorbate using all-atom 
molecular dynamics simulations.  Steered molecular dynamics (SMD) simulations are also 
employed in an attempt to confirm the computationally discovered binding sites of ascorbate by 
comparing the experimentally determined KM with the potential of mean force calculated using 
the Jarzynski relation.  In SMD simulations, external forces are applied in a time-dependent 
manner to, for example, a ligand to facilitate unbinding from an active site.  One can analyze the 
interactions of the unbinding ligand with the pocket, and the applied forces and ligand position as 
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a function of time yielding important structural information about the binding mechanism and 
structure-function relationships of the ligand-receptor complex [19].  By utilizing the Jarzynski 
relationship, one can relate the average potential of mean force derived from a series of SMD 
simulations to the average difference in free energy of two equilibrium states. 
The Jarzynski relationship allows for the use of non-equilibrium calculations of 
equilibrium free energies.  In 1997, Jarzynski proved that: 
              
where ΔG is the Gibbs free energy difference, β is 1/kBT, Wi is the out of equilibrium work done 
onto the system when going from state A to state B, and the exponential average is done over an 
equilibrium ensemble only for state A.  The only requirements for this equality to work are that 
the initial ensemble over state A be equilibrated, and that the exponential average be converged.  
There is, however, no requirement as to how the switch from state A to state B should be done 
(Figure 5.2).   
 Computationally, this is the power of the Jarzynski relationship as there are no 
requirements for how slowly one must switch from state A to state B.  The real advantage of 
employing the Jarzynski relationship is that one only needs to equilibrate the initial state.  This 
eliminates the necessity for a slow, quasi-static transformation from state A to state B.  In an era 
of massively parallel computers available for short spans of time, this type of simulation is ideal 
where a complete Jarzynski style computation can be submitted in parallel and all data collected 
in the time of one simulated pulling.  When small counts of CPUs are available for long periods 
of time, other methods may be preferred. 
Chapter Five: Computational Elucidation of Reductant              Binding Sites in PAM 
 
122 
 
Methods 
Equilibrium Molecular Dynamics 
 The PHM crystal structure (1SDW) was first obtained from the Protein Databank, and all 
catalytically superfluous molecules and ions were removed.  The force field parameters for both 
Cu2+ domains were determined by normal mode analysis in the harmonic approximation.  The 
Hessian was calculated for each methyl-capped Cu-containing fragment (Figure 5.3) separately 
using Density Functional Theory to obtain the bonding and bending force constants.  DFT 
calculations were performed with the B3LYP hybrid exchange-correlation functional and the 6-
31G* basis set.  The equilibrium bond distances were found via geometry optimization.  The 
partial charges of the coppers were the formal charges expected to exist prior to reduction by 
ascorbate.  All other residues used potential parameters from the CHARMM27 force field.   
The PHM system was then solvated in a 120 Å3 water box using the TIP3P water model 
to which Na+ and Cl- counter-ions were added to a concentration of 100 mM.  NAMD was then 
used to equilibrate the system.  All PHM non-backbone atoms were fixed and the system was 
energy minimized for 10,000 steps followed by a minimization of all atoms for 10,000 steps.  
The system was then heated with Cα constrained for 10 ps in the NVT ensemble (T=310.15 K), 
volume equilibrated in the NPT ensemble with Cα  constrained, and free dynamics performed in 
the NPT ensemble (P=1 atm, T=310.15 K) for 2.4 ns (Figure 5.4).  Two separate systems were 
then created using the equilibrated PHM structure to probe for both ascorbate (ASC) and 
mimosine (MIM) binding sites.  The desired probe (ASC or MIM) was added to the solution 
surrounding the equilibrated PHM structure to a concentration of ~10 mM.  A new set of 
counter-ions was added to a concentration of 100mM.  
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All PHM atoms were fixed and the system was energy minimized for 3,000 steps and 
dynamics run for 200 ps on the water and counter-ions.  The ASC or MIM molecules were then 
released and, with PHM still fixed, the system was minimized for 5,000 steps and dynamics was 
performed for 500 ps.  These steps were performed in the NVT ensemble (T=310.15 K).  All 
atoms were then released from constraints, the system minimized for 3,000 steps, and free 
dynamics in the NPT ensemble (P=1 atm, T=310.15 K) run for 80 ns.  All simulations described 
utilized periodic boundary conditions and the Particle Mesh Ewald (PME) method to calculate 
electrostatic forces without cutoff[20].  Van der Waals interactions were calculated with a cutoff 
of 12 Å and a switching distance of 10 Å.  Bonded forces, short range non-bonded forces (within 
the cutoff), and long range electrostatics (outside the cutoff) were evaluated every femtosecond 
during the initial equilibration of the PHM structure.  For the binding simulation, a multiple 
time-stepping algorithm[21, 22] was utilized with a 1 fs step for bonded force evaluation, 2 fs for 
short range non-bonded forces (within the cutoff), and 4 fs for long range electrostatics (outside 
the cutoff).  Langevin dynamics was used to control the temperature using a damping coefficient 
of 5 ps-1 with hydrogen atoms not coupled to the heat bath.  Pressure was regulated via the hybrid 
Nose-Hoover[23] Langevin[24] piston method using a piston oscillation period of 100 fs and a 
damping time scale of 50 fs.   
 
 
Steered Molecular Dynamics 
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 Upon binding of ascorbate or mimosine in their respective simulations, ten starting 
structures from each simulation were collected for multiple steering molecular dynamics 
simulations.   External steering forces were then applied to pull the ligand, ASC or MIM, out of 
its binding site.  The ligands were pulled under constant velocity in directions predetermined 
through visualization, one pull per each of the 20 collected starting structures (Figure 5.5).   
 Bonded forces, short range non-bonded forces (within the cutoff), and long range 
electrostatics (outside the cutoff) were evaluated every femtosecond for all steered molecular 
dynamics simulations.  The pulling velocity was set at 0.00005 Å per time step (1 fs).  A spring 
constant of 7 kcal/mol/Å2 was used to constrain the ligand.  This constraint is large enough to 
allow for the use of the stiff spring approximation[25, 26].  For all pulling simulations, the 
pulling force was applied to the atoms indicated in Figure 5.6.  The force was only applied along 
the pulling direction during the simulation.  The ligands were free from constraint in the plane 
perpendicular to the pulling vector.  Trajectories were saved every 0.1 ps, and steering forces 
recorded every 10 fs.   
Analysis of Trajectories 
 The methods used to construct the potential of mean force (PMF) from the steered 
molecular dynamics simulations were all based on Jarzynski’s equality and were independent of 
the friction coefficient [27].  The reaction coordinate was the increasing distance between the 
ligand and the binding site during the pulling simulation.  Because drifting of the protein would 
change the distance between the ligand and the binding site throughout the simulation, several 
atoms on the side opposite of the binding site were fixed on the protein (Figure 5.7).  
Sp ecifically, these were the Cα of LYS3 3 6  and  ASN3 3 7 .  The u se of 1 0  trajecto ries for both 
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ASC and MIM are sufficient as fewer slower pulling trajectories have been demonstrated to yield 
more accurate PMF values[25, 26].  The 50 Å/ns pulling velocity is sufficiently slow to produce 
accurate PMF values from the number of trajectories used here. 
 The pulling force was calculated using the following equation: 
                                         (1) 
where F is the pulling force, t is time, k is the spring constant of the constraint, v is the pulling 
velocity, n is the pulling direction normal, and r(t) and r0 are the positions of the ligand at time t 
and t0. 
 Work was calculated by integrating the force over the distance pulled from the pulling 
trajectories: 
                                                          (2) 
 The PMF, or free-energy difference, was derived from work W utilizing Jarzynski’s 
equality as follows[26, 28]: 
                                  (3) 
where R is the universal gas constant and T is the absolute temperature.  Previous work by the 
Schulten group has demonstrated that work distribution from Langevin dynamics satisfies a 
Gaussian distribution and can be expressed as a second-order cumulant expansion[26]: 
                                                                      (4) 
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where  is the average work from all trajectories and σW is the standard deviation of the work 
distribution.   
Results 
Ascorbate binding simulations 
 The simulation for the ascorbate binding experiment reveals the probe diffusing though 
the aqueous solution around PHM.  Some of the ligands search the surface of PHM and again 
diffuse.  Some ascorbate molecules in the simulation search the surface and bind to it 
temporarily.  One ascorbate molecule in the simulation, however, binds and remains bound for 
15 ns.  The criteria for determining the legitimacy of a binding site included two important 
guidelines.  The binding site must be a depressed, hydrophobic pocket and not simply hydrogen 
bonding interactions on the surface of PHM.  The binding should last on the order of >10 ns to 
ensure sufficient interaction strength.  The ascorbate simulation was carried out for 79 ns and 
revealed only one potential binding site for ascorbate (Figure 5.8). 
 The binding site for ascorbate is a depression on the PHM surface that includes residues 
important for strong hydrogen bonding.  These residues include ASP61, GLN198, and LYS152.  
A frame from the trajectory during the “ascorbate on” portion of the simulation is rendered 
below (Figure 5.9). 
 As a means of measuring the amount of time the particular binding ascorbate ligand spent 
bound to the enzyme, hydrogen bonding was monitored between the ascorbate ligand and the 
surface of PHM.  The data indicates that ascorbate bound to PHM for ~15 ns before diffusing.  
This meets our criteria for legitimate binding and is depicted in Figure 5.10. 
Mimosine binding simulations 
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 The simulation for the mimosine binding experiment was performed in the same manner 
as that of the ascorbate binding experiment.  Mimosine diffused freely throughout the solvent 
during the simulation.  The mimosine simulation was carried out for ~82 ns, and only one 
potential binding site for mimosine was identified (Figure 5.11). 
 The binding site for mimosine is a depression on the PHM surface much like that of 
ascorbat and includes residues important for strong hydrogen bonding.  The binding site residues 
include ASN45, ARG67, ARG100, and LYS98.  A frame from the trajectory during the 
mimosine bound portion of the simulation is rendered in Figure 5.12. 
 In order to determine the amount of time mimosine was bound to PHM during the 
simulations, the hydrogen bonding between the bound ligand and the binding site was 
investigated.  Figure 5.13 illustrates that mimosine seemed to bind longer than ascorbate perhaps 
suggesting a stronger interaction which would be consistent with what has been observed 
experimentally.   
 Because ascorbate and mimosine were shown to bind in close proximity but different 
binding pockets, the particle mesh Ewald electrostatic potential of PHM was calculated for the 
“on” and “off” states of both ligands.  This illustrates that the electrostatic effects of mimosine 
binding would indeed affect the binding pocket of ascorbate.  Thus, the seemingly competitive 
experimental data may not rule out slightly differing binding sites within a few angstroms of one 
another (Figures 5.14 & 5.15). 
Steered Molecular Dynamics 
 The SMD simulations for both ascorbate and mimosine yielded force data that fluctuate 
between positive and negative values (Figure 5.16).  This indicates that the thermal fluctuation of 
the ligand (ASC or MIM) is larger than the perturbation from the pulling.  This shows that the 
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process by which the ligand unbinds is near equilibrium.  No conformational changes were seen 
during the unbinding process with mild peaks in the force graph relating only to the breaking of 
hydrogen bonds.  
 The unbinding of the two ligands, ascorbate and mimosine, are nonequilibrium processes.  
The external work was sampled from repeated trajectories in order to calculate the potential of 
mean force using the Jarzynski equality (Figure 5.17).  Jarzynski’s equality cannot be used 
directly unless the deviation of work distribution  ≤ 4kT which is generally not true for 
biological systems of the size simulated here[19].  Because standard deviation will grow as the 
ligand is pulled further from the binding site, the free energy estimated from the Jarzynski 
equality is dominated by smaller values of work.  The cumulant expansion method was 
developed to solve this problem[25, 26] (Figure 5.18).  Utilizing the cumulant expansion method 
improves the statistics of work distribution caused by having such limited sampling when 
calculating the PMF.  
Discussion 
 The simulations performed in an attempt to elucidate the binding site for ascorbate, the 
reductant of PAM, have led to the discovery of a possible binding site.  The successful 
elucidation of a binding site will help eliminate some of the proposed mechanisms and help 
determine where electron transfer occurs prior to the reduction of CuM.  The mimosine 
simulation was used as a control in that an ascorbate binding site would either accommodate 
mimosine or a mimosine binding site would be very nearby.  This proved to be the case in the 
proposed ascorbate binding site.  Mimosine binds within a few angstroms of ascorbate.   
 Another method used as a way of verifying the proposed binding site was the calculation 
of the free energy of binding.  While the calculated free energy for mimosine can be directly 
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compared with the experimental KI value (4 µM) as no chemistry is occurring, that of ascorbate 
is a KM (223 µM) and cannot be compared directly but is a good estimate.  Using the equations 
for Gibbs free energy: 
                                                                  (5) 
where K is the Kd or KM for mimosine and ascorbate, respectively, calculated from the PMF 
values for free energy simulated.  The calculated PMF values for ascorbate yields a theoretical 
KM of 200 µM.  This is sufficiently close to justify consideration of the proposed binding site as 
valid.  The theoretical KI of mimosine from the simulation results in a value of 1 µM which is 
also consistent with the experimental data within the accepted error for this type of free energy 
calculation.   
 While initial results are convincing, more work is needed to experimentally verify these 
initial findings.  Mutants targeting the proposed binding site should be made and the effects of 
these mutations tested on reduction of PAM by ascorbate.  A quicker method may be to perform 
in silico docking of a library of commercially available compounds.  Hits for binding in the 
proposed binding site should be tested as competitive inhibitors against the reduction of PAM by 
ascorbate. 
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Figures and Tables 
Figures 
 
Figure 5.1. Peptidylglycine α-amidating monooxygenase reaction.  Note, Asc represents 
ascorbate, deAsc represents semidehydroascorbate, PAM is peptidylglycine a-amidating 
monooxygenase, PHM is peptidylglycine α-hydroxylating monooxygenase, and PAL is 
peptidylgycine amidoglycolate lyase. 
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Figure 5.2.  States A and B in which state A is the starting structure and state B is the final state 
post SMD simulation.  Water and ions omitted for clarity. 
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Figure 5.3.  Methyl-capped CuH and CuM domains in the PHM crystal structure prior to 
geometry optimization. 
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Figure 5.4.  PHM crystal structure “soaked” with ascorbate.  Note, water and ions not shown for 
clarity. 
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Figure 5.5.  Illustration of the PHM secondary structure with bound ascorbate and the spring as 
the force vector applied during the steering molecular dynamics simulations. 
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Figure 5.6.  Ascorbate and mimosine used to probe for a reductant binding site on PHM and the 
carbon atoms in which the force was applied during the steered molecular dynamics simulation. 
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Figure 5.7.  PHM secondary structure with bound ascorbate and the fixed L336 and N337. 
 
Chapter Five: Computational Elucidation of Reductant              Binding Sites in PAM 
 
140 
 
 
 
 
 
 
 
Figure 5.8.  Ascorbate bound to the surface of PHM. 
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Figure 5.9.  Ascorbate in the proposed binding pocket with hydrogen bonding illustrated as blue 
or red dashed lines. 
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Figure 5.10.  Hydrogen bonding between ascorbate and the proposed PHM binding site. 
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Figure 5.11.  Mimosine bound to the surface of PHM. 
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Figure 5.12.  Mimosine in the proposed binding pocket with hydrogen bonding illustrated as 
blue dashed lines. 
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Figure 5.13. Hydrogen bonding between mimosine and the proposed PHM binding site. 
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Figure 5.14. PME electrostatic potential of PHM with “off” and “on” ascorbate. 
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Figure 5.15.  PME electrostatic potential of PHM with “off” and “on” mimosine. 
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Figure 5.16.  Force vs extension for both ascorbate and mimosine over a 5 Å reaction 
coordinate. 
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Figure 5.17.  Work vs extension for ascorbate and mimosine unbinding. 
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Figure 5.18. Potential of mean force vs extension for ascorbate and mimosine unbinding. 
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Appending A 
PCGAMESS Geometry Optimization Settings 
File 1. L3Cu(I)-thiophenolate geometry optimization (truncated) 
! Geometry optimize the CuM cluster with thiophenolate anion coordinated 
! (froze the carbons of the methyl caps to simulated the protein backbone) 
! lanl2dz basis set 
! 
! Jon Belof/Edward W. Lowe 
! Department of Chemistry 
! University of South Florida 
! 
 $CONTRL SCFTYP=RHF RUNTYP=OPTIMIZE MAXIT=200 ECP=READ $END 
 $SYSTEM TIMLIM=9999999999 MWORDS=70 $END 
 $STATPT NSTEP=1000 IFREEZ(1)=10,11,12,13,14,15,16,17,18 $END 
 $DFT DFTTYP=B3LYP $END 
 $GUESS GUESS=HUCKEL $END 
 $ECP  
  CU-ECP GEN     10     2 
  3      ----- d potential     ----- 
    -10.0000000        1    511.9951763         
    -72.5548282        2     93.2801074         
    -12.7450231        2     23.2206669         
  4      ----- s-d potential     ----- 
      3.0000000        0    173.1180854         
     23.8351825        1    185.2419886         
    473.8930488        2     73.1517847         
    157.6345823        2     14.6884157         
  4      ----- p-d potential     ----- 
      5.0000000        0    100.7191369         
      6.4990936        1    130.8345665         
    351.4605395        2     53.8683720         
     85.5016036        2     14.0989469         
  S-ECP GEN     10     2 
  5      ----- d   potential     ----- 
    -10.0000000        1    532.6685222         
    -85.3593846        2    108.1342248         
    -30.4513290        2     24.5697664         
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    -10.3745886        2      7.3702438         
     -0.9899295        2      2.3712569         
  5      ----- s-d potential     ----- 
      3.0000000        0    106.3176781         
     10.6284036        1    100.8245833         
    223.6360469        2     53.5858472         
     93.6460845        2     15.3706332         
     28.7609065        2      3.1778402         
  6      ----- p-d potential     ----- 
      5.0000000        0    101.9709185         
      6.0969842        1     93.2808973         
    285.4425500        2     65.1431772         
    147.1448413        2     24.6347440         
     53.6569778        2      7.8120535         
      8.9249559        2      2.3112730         
$END 
 $DATA 
 
File 2. L3Cu(I)-H2O geometry optimization (truncated) 
 
! Geopt of CuM cluster with frozen methyl caps and water coordinated lanl2dz 
! Edward W. Lowe Jr 
! Merkler Research Group 
! Department of Chemistry 
! University of South Florida 
 $CONTRL SCFTYP=RHF RUNTYP=OPTIMIZE ICHARG=+1 MULT=1 UNITS=ANGS 
$END 
 $CONTRL INTTYP=HONDO ICUT=10 MAXIT=1000 ECP=READ $END 
 $SYSTEM TIMLIM=9999999999 MWORDS=70 $END 
 $SMP CSMTX=.T. $END 
 $P2P P2P=.T. DLB=.T. $END 
 $SCF DIRSCF=.TRUE. FDIFF=.FALSE. SOSCF=.FALSE. $END 
 $SCF DIIS=.TRUE. DAMP=.T. ETHRSH=2.0 $END 
 $STATPT NSTEP=1000 OPTTOL=0.00001 HESS=CALC $END 
 $STATPT IFREEZ(1)=1,2,3,19,20,21,37,38,39 $END 
 $DFT DFTTYP=B3LYP $END 
 $GUESS GUESS=HUCKEL $END 
 $ECP  
  CU-ECP GEN     10     2 
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  3      ----- d potential     ----- 
    -10.0000000        1    511.9951763         
    -72.5548282        2     93.2801074         
    -12.7450231        2     23.2206669         
  4      ----- s-d potential     ----- 
      3.0000000        0    173.1180854         
     23.8351825        1    185.2419886         
    473.8930488        2     73.1517847         
    157.6345823        2     14.6884157         
  4      ----- p-d potential     ----- 
      5.0000000        0    100.7191369         
      6.4990936        1    130.8345665         
    351.4605395        2     53.8683720         
     85.5016036        2     14.0989469         
  S-ECP GEN     10     2 
  5      ----- d   potential     ----- 
    -10.0000000        1    532.6685222         
    -85.3593846        2    108.1342248         
    -30.4513290        2     24.5697664         
    -10.3745886        2      7.3702438         
     -0.9899295        2      2.3712569         
  5      ----- s-d potential     ----- 
      3.0000000        0    106.3176781         
     10.6284036        1    100.8245833         
    223.6360469        2     53.5858472         
     93.6460845        2     15.3706332         
     28.7609065        2      3.1778402         
  6      ----- p-d potential     ----- 
      5.0000000        0    101.9709185         
      6.0969842        1     93.2808973         
    285.4425500        2     65.1431772         
    147.1448413        2     24.6347440         
     53.6569778        2      7.8120535         
      8.9249559        2      2.3112730         
$END 
 $DATA 
File 3. L3Cu(I) geometry optimization (truncated) 
 
! Geometry optimize the CuM cluster with no water coordinated 
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! (froze the carbons of the methyl caps to simulated the protein backbone) 
! lanl2dz 
! Jon Belof/Edward W. Lowe 
! Department of Chemistry 
! University of South Florida 
! 
 $CONTRL SCFTYP=RHF RUNTYP=OPTIMIZE ICHARG=1 MAXIT=200 ECP=READ 
$END 
 $SYSTEM TIMLIM=9999999999 MWORDS=235 $END 
 $STATPT NSTEP=200 IFREEZ(1)=10,11,12,13,14,15,16,17,18 $END 
 $DFT DFTTYP=B3LYP $END 
 $GUESS GUESS=HUCKEL $END 
 $ECP  
  CU-ECP GEN     10     2 
  3      ----- d potential     ----- 
    -10.0000000        1    511.9951763         
    -72.5548282        2     93.2801074         
    -12.7450231        2     23.2206669         
  4      ----- s-d potential     ----- 
      3.0000000        0    173.1180854         
     23.8351825        1    185.2419886         
    473.8930488        2     73.1517847         
    157.6345823        2     14.6884157         
  4      ----- p-d potential     ----- 
      5.0000000        0    100.7191369         
      6.4990936        1    130.8345665         
    351.4605395        2     53.8683720         
     85.5016036        2     14.0989469         
  S-ECP GEN     10     2 
  5      ----- d   potential     ----- 
    -10.0000000        1    532.6685222         
    -85.3593846        2    108.1342248         
    -30.4513290        2     24.5697664         
    -10.3745886        2      7.3702438         
     -0.9899295        2      2.3712569         
  5      ----- s-d potential     ----- 
      3.0000000        0    106.3176781         
     10.6284036        1    100.8245833         
    223.6360469        2     53.5858472         
Appendices 
 
155 
 
     93.6460845        2     15.3706332         
     28.7609065        2      3.1778402         
  6      ----- p-d potential     ----- 
      5.0000000        0    101.9709185         
      6.0969842        1     93.2808973         
    285.4425500        2     65.1431772         
    147.1448413        2     24.6347440         
     53.6569778        2      7.8120535         
      8.9249559        2      2.3112730         
$END 
 $DATA 
 
File 4. L3Cu(II) geometry optimization of CuM for NAMD parameterization 
 
 !Optimization of CuM for the ascorbate binding site probe using NAMD 
 !Edward W. Lowe 
 !Merkler Research Group 
 !University of South Florida 
 !05/04/07 
 $CONTRL SCFTYP=UHF RUNTYP=OPTIMIZE ICHARG=+2 MULT=2 $END 
 $CONTRL INTTYP=HONDO ICUT=10 MAXIT=75 ECP=SBK $END 
 $SYSTEM KDIAG=0 TIMLIM=999999999 MWORDS=23 $END 
 $SMP CSMTX=.T. $END 
 $P2P P2P=.T. DLB=.T. $END 
 $TRANS AOINTS=DIST $END 
 $SCF DIRSCF=.T. FDIFF=.F. SOSCF=.F. DIIS=.T. ETHRSH=2.0 $END 
 $STATPT NSTEP=1000 HESS=CALC $END 
 $STATPT IFREEZ(1)=13,14,15 $END 
 $STATPT IFREEZ(2)=49,50,51 $END 
 $STATPT IFREEZ(3)=76,77,78 $END 
 $DFT DFTTYP=B3LYP $END 
 $GUESS GUESS=HUCKEL $END 
 $BASIS GBASIS=SBK $END 
 $DATA 
CuM with water for thiol paper geopt 
C1 
H    1.0    -1.40800  -6.66500   0.02200  
N    7.0    -0.45700  -3.88900   0.20500  
H    1.0    -1.36400  -3.51400   0.01000  
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C    6.0    -0.18600  -5.13500   0.72900  
C    6.0    -1.21300  -6.20000   0.90400  
H    1.0    -2.05800  -5.78700   1.49600  
H    1.0    -0.78100  -7.03400   1.50000  
N    7.0     1.71100  -3.96100   0.53200  
C    6.0     1.16200  -5.16900   0.92700  
H    1.0     1.78700  -5.97500   1.29300  
C    6.0     0.71100  -3.21300   0.11000  
H    1.0     0.79400  -2.18800  -0.26100  
H    1.0     2.80000  -3.66700  -5.08200  
N    7.0     5.63800  -3.10800  -3.17700  
H    1.0     6.42700  -3.01200  -3.78500  
C    6.0     4.32400  -3.25600  -3.56400  
C    6.0     3.86900  -3.38000  -4.98500  
H    1.0     4.47300  -4.16500  -5.49000  
H    1.0     4.06600  -2.42700  -5.52400  
N    7.0     4.45300  -3.06700  -1.32800  
C    6.0     3.59600  -3.23700  -2.41500  
H    1.0     2.53000  -3.36200  -2.27000  
C    6.0     5.66700  -2.99600  -1.83500  
H    1.0     6.58300  -2.85800  -1.25400  
H    1.0     4.93600  -7.63500  -1.24100  
C    6.0     4.39500  -7.14200  -0.41800  
H    1.0     3.73600  -6.41300  -0.94600  
H    1.0     3.74900  -7.66600   0.32100  
C    6.0     5.53200  -6.39500   0.26700  
H    1.0     6.24300  -7.11300   0.72800  
H    1.0     6.09500  -5.80000  -0.48500  
S   16.0     4.86300  -5.30900   1.55000  
C    6.0     6.42100  -4.66400   2.29100  
H    1.0     6.20300  -3.96700   3.12800  
H    1.0     7.04600  -5.49200   2.69000  
H    1.0     7.02400  -4.11300   1.53700  
Cu  29.0     3.77600  -3.54100   0.63000  
 $END 
 
File 5. L3Cu(II) geometry optimization of CuH for NAMD parameterization 
 
 !Optimization of CuH for the ascorbate binding site probe using NAMD 
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 !Edward W. Lowe 
 !Merkler Research Group 
 !University of South Florida 
 !05/04/07 
 $CONTRL SCFTYP=UHF RUNTYP=OPTIMIZE ICHARG=+2 MULT=2 $END 
 $CONTRL INTTYP=HONDO ICUT=10 MAXIT=75 ECP=SBK $END 
 $SYSTEM KDIAG=0 TIMLIM=999999999 MWORDS=235 AOINTS=DIST $END 
 $SMP CSMTX=.T. $END 
 $P2P P2P=.T. DLB=.T. $END 
 $SCF DIRSCF=.T. FDIFF=.F. SOSCF=.F. DIIS=.T. ETHRSH=2.0 $END 
 $STATPT NSTEP=1000 HESS=CALC $END 
 $STATPT IFREEZ(1)=13,14,15 $END 
 $STATPT IFREEZ(2)=49,50,51 $END 
 $STATPT IFREEZ(3)=76,77,78 $END 
 $DFT DFTTYP=B3LYP $END 
 $BASIS GBASIS=SBK $END 
 $GUESS GUESS=HUCKEL $END 
 $DATA 
CuH rxn center geopt 
C1 
H    1.0      -6.119     6.698     -0.238 
N    7.0      -5.674     4.283     -3.250 
H    1.0      -5.965     3.920     -4.135 
C    6.0      -5.797     5.589     -2.834 
H    1.0      -6.243     6.369     -3.435 
N    7.0      -4.798     4.407     -1.231 
C    6.0      -5.252     5.651     -1.592 
C    6.0      -5.067     3.616     -2.254 
H    1.0      -4.824     2.551     -2.295 
C    6.0      -5.148     6.819     -0.667 
H    1.0      -4.962     7.729     -1.277 
H    1.0      -4.279     6.702     0.014 
H    1.0      -5.795     4.086     2.649 
N    7.0      -2.530     2.247     3.704 
H    1.0      -1.878     1.910     4.382 
C    6.0      -3.893     2.373     3.885 
H    1.0      -4.401     2.121     4.805 
N    7.0      -3.372     2.999     1.816 
C    6.0      -4.395     2.839     2.714 
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C    6.0      -2.272     2.635     2.446 
H    1.0      -1.273     2.641     2.003 
C    6.0      -5.816     3.154     2.352 
H    1.0      -6.449     2.318     2.719 
H    1.0      -5.927     3.185     1.248 
H    1.0      -2.117     7.001     2.768 
N    7.0      -0.484     6.682     -0.781 
H    1.0       0.160     7.116     -1.410 
C    6.0      -0.652     7.001     0.549 
H    1.0      -0.097     7.779     1.053 
N    7.0      -2.017     5.319     0.023 
C    6.0      -1.598     6.155     1.030 
C    6.0      -1.325     5.669     -1.046 
H    1.0      -1.416     5.195     -2.026 
C    6.0      -2.160     6.049     2.414 
H    1.0      -1.639     5.214     2.931 
H    1.0      -3.237     5.784     2.373 
Cu  29.0      -3.637     3.998     0.110 
 $END 
 
File 6. Geometry optimization of ascorbate for NAMD parameterization 
 
 $CONTRL SCFTYP=RHF RUNTYP=OPTIMIZE ICHARG=0 MULT=1 COORD=ZMT 
NZVAR=54 $END 
 $CONTRL MAXIT=75 $END 
 $SYSTEM TIMLIM=999999999 MWORDS=235 $END 
 $SCF DIRSCF=.TRUE. $END 
 $STATPT NSTEP=1000 $END 
 $BASIS GBASIS=N31 NGAUSS=6 $END 
 $ELPOT IEPOT=1 WHERE=PDC $END 
 $PDC PTSEL=CONNOLLY CONSTR=CHARGE $END 
 $FORCE PURIFY=.TRUE. PRTIFC=.TRUE. DECOMP=.TRUE. $END 
 $ZMAT IZMAT(1)=1,2,1,1,3,2,1,4,3,1,5,4,1,6,2,1,7,4,1,8,7,1,9,5, 
                1,10,1,1,11,7,1,12,11,1,13,4,1,14,7,1,15,11,1,16,11, 
                1,17,12,1,18,8,1,19,10,1,20,9, 
                2,3,2,1,2,4,3,2,2,5,4,3,2,6,2,3,2,7,4,3,2,8,7,4, 
                2,9,5,4,2,10,1,2,2,11,7,4,2,12,11,7,2,13,4,3,2,14,7,4, 
                2,15,11,7,2,16,11,7,2,17,12,11,2,18,8,7,2,19,10,1,2,20,7,5, 
                3,4,3,2,1,3,5,4,3,2,3,6,2,3,4,3,7,4,3,2,3,8,7,4,3, 
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                3,9,5,4,3,3,10,1,2,3,3,11,7,4,3,3,12,11,7,4,3,13,4,3,2, 
                3,14,7,4,3,3,15,11,7,4,3,16,11,7,4,3,17,12,11,7,3,18,8,7,4, 
                3,19,10,1,2,3,20,9,5,4  
 $END 
 $DATA 
 ascorbate toppar 
C1 
 C    
 O      1   1.3993695 
 C      2   1.4911748  1   109.3353707 
 C      3   1.5083526  2   102.8105937  1     0.4558029  0 
 C      4   1.3447000  3   110.2718397  2    -0.5401568  0 
 C      3   1.5288325  2   108.6056231  1  -123.6554732  0 
 C      6   1.5314014  3   113.7297864  2   172.2854080  0 
 O      7   1.4620625  6   103.6177438  3   171.2245510  0 
 O      6   1.4454707  3   105.7709296  2   -68.4700166  0 
 O      1   1.2312353  2   124.4287108  3  -179.7704008  0 
 O      5   1.3768209  4   126.8178161  3   179.5237568  0 
 O      4   1.3704297  3   119.9144041  2   178.6049028  0 
 H      3   1.0945449  2   106.7457350  1   119.0405695  0 
 H      6   1.0991831  3   108.6614051  2    50.6657410  0 
 H      7   1.0937666  6   111.7872871  3   -68.8319724  0 
 H      7   1.0980365  6   110.1003640  3    52.5684184  0 
 H      8   0.9758375  7   111.3198901  6  -171.5451546  0 
 H      9   0.9819455  6   107.0046583  3  -170.4584470  0 
 H     11   0.9808199  5   109.9007971  4  -178.8505208  0 
 H     12   0.9799619  4   111.6479499  3  -177.6398852  0 
 $END 
 
File 7. Geometry optimization of mimosine for NAMD parameterization 
 
 $CONTRL SCFTYP=RHF RUNTYP=OPTIMIZE ICHARG=-1 MULT=1 COORD=ZMT 
NZVAR=63 $END 
 $CONTRL MAXIT=75 $END 
 $SYSTEM TIMLIM=999999999 MWORDS=235 $END 
 $SCF DIRSCF=.TRUE. $END 
 $STATPT NSTEP=1000 $END 
 $BASIS GBASIS=N31 NGAUSS=6 $END 
 $ELPOT IEPOT=1 WHERE=PDC $END 
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 $PDC PTSEL=CONNOLLY CONSTR=CHARGE $END 
 $FORCE PURIFY=.TRUE. PRTIFC=.TRUE. DECOMP=.TRUE. $END 
 $DATA 
 mimosine toppar 
C1 
 c 
 c   1 cc2      
 c   2 cc3        1 ccc3       
 n   3 nc4        2 ncc4         1 dih4    
 c   4 cn5        3 cnc5         2 dih5    
 c   5 cc6        4 ccn6         3 dih6    
 o   2 oc7        3 occ7         4 dih7    
 c   4 cn8        3 cnc8         2 dih8    
 c   8 cc9        4 ccn9         3 dih9    
 n   9 nc10       8 ncc10        4 dih10   
 o   1 oc11       2 occ11        3 dih11   
 c   9 cc12       8 ccc12        4 dih12   
 o  12 oc13       9 occ13        8 dih13   
 o  12 oc14       9 occ14        8 dih14   
 h   3 hc15       2 hcc15        1 dih15   
 h   5 hc16       4 hcn16        3 dih16   
 h   6 hc17       5 hcc17        4 dih17   
 h   7 ho18       2 hoc18        3 dih18   
 h   8 hc19       4 hcn19        3 dih19   
 h   8 hc20       4 hcn20        3 dih20   
 h   9 hc21       8 hcc21        4 dih21   
 h  10 hn22       9 hnc22        8 dih22   
 h  10 hn23       9 hnc23        8 dih23   
 
 cc2         1.409701 
 cc3         1.399166 
 ccc3        118.654 
 nc4         1.368604 
 ncc4        121.037 
 dih4         -0.201 
 cn5         1.367139 
 cnc5        120.411 
 dih5          0.620 
 cc6         1.395360 
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 ccn6        120.605 
 dih6         -0.665 
 oc7         1.380548 
 occ7        118.403 
 dih7        179.856 
 cn8         1.472220 
 cnc8        119.482 
 dih8        179.991 
 cc9         1.541563 
 ccn9        111.386 
 dih9         71.975 
 nc10        1.463633 
 ncc10       109.893 
 dih10      -177.868 
 oc11        1.350598 
 occ11       121.154 
 dih11       179.946 
 cc12        1.507657 
 ccc12       110.483 
 dih12        60.722 
 oc13        1.225477 
 occ13       120.220 
 dih13        73.235 
 oc14        1.352379 
 occ14       119.610 
 dih14       -96.438 
 hc15        1.083728 
 hcc15       118.813 
 dih15       179.605 
 hc16        0.983454 
 hcn16       120.565 
 dih16       179.918 
 hc17        1.083065 
 hcc17       119.985 
 dih17      -179.661 
 ho18        0.990257 
 hoc18       109.377 
 dih18      -179.940 
 hc19        1.114040 
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 hcn19       110.876 
 dih19      -166.298 
 hc20        1.112321 
 hcn20       109.145 
 dih20       -49.392 
 hc21        1.113838 
 hcc21       109.120 
 dih21       -58.779 
 hn22        1.046531 
 hnc22       108.316 
 dih22       177.274 
 hn23        1.046012 
 hnc23       108.372 
 dih23        62.789 
 $END 
 
File 8. General input for all PBA geometry optimizations 
 
 $CONTRL ICHARG=-1 MULT=1 RUNTYP=OPTIMIZE SCFTYP=RHF COORD=CART 
$END 
 $CONTROL UNITS=ANGS MAXIT=200 $END 
 $DFT DFTTYP=B3LYP METHOD=GRID $END 
 $BASIS GBASIS=N31 NGAUSS=6 $END 
 $STATPT METHOD=QA NSTEP=1000 OPTTOL=0.0001 HESS=CALC $END 
 $GUESS GUESS=HUCKEL $END 
 $SYSTEM MWORDS=200 $END 
 $P2P P2P=.T. DLB=.T. $END 
 $DATA 
pba geopt  
C1 
C    6.0    -1.21290   1.62180   0.02210  
C    6.0    -1.98910   2.79560  -0.04280  
C    6.0    -3.38860   2.68230  -0.12420  
C    6.0    -4.00030   1.42460  -0.11890  
C    6.0    -3.22200   0.26740  -0.04100  
C    6.0    -1.82980   0.36600   0.02630  
H    1.0    -0.13300   1.66350   0.04760  
C    6.0    -1.37430   4.14610  -0.05840  
H    1.0    -3.95040   3.48720  -0.17960  
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H    1.0    -5.07890   1.34760  -0.17620  
H    1.0    -3.65420  -0.61520  -0.03880  
H    1.0    -1.28160  -0.44850   0.07100  
C    6.0     0.01850   4.41530   0.37530  
C    6.0     0.57530   5.65830   0.28230  
C    6.0     1.76220   5.62260  -0.63100  
O    8.0     1.58680   5.73260  -1.96700  
O    8.0     2.97600   5.27760  -0.14560  
H    1.0    -1.93810   4.91010  -0.32520  
H    1.0     0.60170   3.62470   0.83730  
H    1.0    -0.15140   6.40800  -0.10090  
H    1.0     0.89630   5.99040   1.29280  
$END 
 
File 9. General input for PBA single point energy calculations 
 
$CONTRL COORD=CART ICHARG=-1 MAXIT=200 MPLEVL=2 
MULT=1 RUNTYP=ENERGY SCFTYP=RHF UNITS=ANGS 
 $END 
 $BASIS DIFFS=.true. GBASIS=N311 NDFUNC=2 
NFFUNC=1 NGAUSS=6 NPFUNC=1 POLAR=HONDO7 
 $END 
 $SCF DAMP=.false. DEM=.false. DIIS=.false. 
DIRSCF=.true. EXTRAP=.true. RSTRCT=.false. 
SHIFT=.false. SOSCF=.true.  
 $END 
 $STATPT METHOD=QA NSTEP=1000 OPTTOL=0.001 
 $END 
 $P2P P2P=.T. DLB=.T. $END 
 $FORCE TEMP=0 
 $END 
 $GUESS  
GUESS=HUCKEL 
 $END 
 $SYSTEM  
MWORDS=100 
 $END 
 $DATA 
high level spe for RSE 
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C1 
C    6.0     1.64210   1.04520   0.01360  
C    6.0     1.39220  -0.33140   0.06250  
C    6.0     2.49530  -1.18880   0.02550  
C    6.0     3.79150  -0.69980  -0.04000  
C    6.0     4.02160   0.66700  -0.07370  
C    6.0     2.93620   1.53430  -0.04800  
H    1.0     0.81830   1.73130   0.00850  
C    6.0     0.03280  -0.89950   0.14130  
H    1.0     2.33020  -2.25030   0.05320  
H    1.0     4.61830  -1.38580  -0.06430  
H    1.0     5.02340   1.05040  -0.12550  
H    1.0     3.09770   2.59580  -0.08560  
C    6.0    -1.07700  -0.24630   0.47900  
C    6.0    -2.44780  -0.83830   0.54640  
C    6.0    -3.55620   0.11790   0.02940  
O    8.0    -4.58990  -0.44840  -0.40270  
O    8.0    -3.31650   1.35010   0.14560  
H    1.0    -0.03150  -1.94980  -0.09300  
H    1.0    -1.05380   0.79980   0.72080  
H    1.0    -2.51460  -1.77740   0.01190  
H    1.0    -2.69920  -1.04500   1.58790  
$END 
 
File 10. General input for PBA radical geometry optimizations (truncated) 
 
 $CONTRL ICHARG=-1 MULT=2 RUNTYP=OPTIMIZE SCFTYP=UHF COORD=CART 
$END 
 $CONTROL UNITS=ANGS MAXIT=200 $END 
 $DFT DFTTYP=B3LYP METHOD=GRID $END 
 $BASIS GBASIS=N31 NGAUSS=6 $END 
 $STATPT METHOD=QA NSTEP=1000 OPTTOL=0.0001 HESS=CALC $END 
 $GUESS GUESS=HUCKEL $END 
 $SYSTEM MWORDS=200 $END 
 $P2P P2P=.T. DLB=.T. $END 
 $DATA 
pba radical geopt  
 
File 11. General input for PBA radical single point energy calculations (truncated) 
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$CONTROL RUNTYP=ENERGY COORD=CART ICHARG=-1 MULT=2 $END 
 $CONTROL MAXIT=200 MPLEVL=2 SCFTYP=UHF UNITS=ANGS $END 
 $BASIS GBASIS=N311 NDFUNC=2 NFFUNC=1 NGAUSS=6 NPFUNC=1 $END 
 $STATPT NSTEP=1000 $END 
 $GUESS GUESS=HUCKEL $END 
 $SYSTEM MWORDS=200 $END 
 $DATA 
 high level spe for RSE 
 
 
File 12. General input for cinnamate analog geometry optimizations (truncated) 
 
 $CONTRL ICHARG=-1 MULT=1 RUNTYP=OPTIMIZE SCFTYP=RHF COORD=CART 
$END 
 $CONTRL UNITS=ANGS MAXIT=10000 $END 
 $SYSTEM KDIAG=0 TIMLIM=999999999 AOINTS=DIST $END 
 $SMP CSMTX=.T. $END 
 $P2P P2P=.T. DLB=.T. $END 
 $SCF DIRSCF=.T. FDIFF=.F. SOSCF=.F. DIIS=.T. ETHRSH=2.0 $END 
 $DFT DFTTYP=B3LYP METHOD=GRID $END 
 $BASIS GBASIS=N31 NGAUSS=6 $END 
 $STATPT METHOD=QA NSTEP=1000 OPTTOL=0.0001 HESS=CALC $END 
 $GUESS GUESS=HUCKEL $END 
 $SYSTEM MWORDS=200 $END 
 $P2P P2P=.T. DLB=.T. $END 
 $DATA 
 
Appendix B 
 
PCGAMESS Hessian Calculation Input Files 
 
File 13. Hessian calculation for L3Cu(I) CuM for NAMD parameterization (truncated) 
 
 $CONTRL SCFTYP=RHF RUNTYP=HESSIAN ICHARG=+1 MULT=1 COORD=ZMT 
NZVAR=105 $END 
 $CONTRL MAXIT=100 ECP=SBK $END 
 $SYSTEM TIMLIM=9999999999 MWORDS=200 $END 
 $SCF DIRSCF=.TRUE. $END 
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 $STATPT NSTEP=1000 HESS=CALC $END 
 $GUESS GUESS=HUCKEL $END 
 $BASIS GBASIS=SBK $END 
 $ELPOT IEPOT=1 WHERE=PDC $END 
 $PDC PTSEL=CONNOLLY CONSTR=CHARGE $END 
 $FORCE PURIFY=.TRUE. PRTIFC=.TRUE. DECOMP=.TRUE. $END 
 $ZMAT IZMAT(1)=1,2,1,1,3,2,1,4,2,1,5,1,1,6,5,1,7,5,1,8,2,1,9,4,1,10,9, 
1,11,8,1,12,11,1,13,8,1,14,13,1,15,14,1,16,14,1,17,13,1,18,17,1,19,17, 
1,20,14,1,21,16,1,22,21,1,23,20,1,24,23,1,25,24,1,26,25,1,27,26,1,28,26, 
1,29,26,1,30,29,1,31,29,1,32,29,1,33,32,1,34,33,1,35,33,1,36,33,1,37,20, 
2,3,2,1,2,4,2,1,2,5,1,2,2,6,5,1,2,7,5,1,2,8,2,1,2,9,4,2,2,10,9,4,2,11,8,2, 
2,12,11,8,2,13,8,2,2,14,13,8,2,15,14,13,2,16,14,13,2,17,13,8,2,18,17,13, 
2,19,17,13,2,20,14,13,2,21,16,14,2,22,21,16,2,23,20,14,2,24,23,20,2,25,24,23, 
2,26,25,24,2,27,26,25,2,28,26,25,2,29,26,25,2,30,29,26,2,31,29,26,2,32,29,26, 
2,33,32,29,2,34,33,32,2,35,33,32,2,36,33,32,2,37,20,14,3,4,2,1,3,3,5,1,2,3,3,6,5,1,2,3,7,5,1,2,3,8,
2,1,3,3,9,4,2,1,3,10,9,4,2,3,11,8,2,1,3,12,11,8,2,3,13,8,2,1,3,14,13,8,2,3,15,14,13,8,3,16,14,13,8,
3,17,13,8,2,3,18,17,13,8,3,19,17,13,8,3,20,14,13,8,3,21,16,14,13,3,22,21,16,14,3,23,20,14,13,3,2
4,23,20,14,3,25,24,23,20,3,26,25,24,23,3,27,26,25,24,3,28,26,25,24,3,29,26,25,24,3,30,29,26,25,
3,31,29,26,25,3,32,29,26,25,3,33,32,29,26,3,34,33,32,29,3,35,33,32,29,3,36,33,32,29,3,37,20,14,
13, 
 $END 
 $DATA 
 
File 14. Hessian calculation for L3Cu(II) CuM for NAMD parameterization (truncated) 
 
 $CONTRL SCFTYP=RHF RUNTYP=HESSIAN ICHARG=+2 MULT=2 COORD=ZMT 
NZVAR=105 $END 
 $CONTRL MAXIT=100 ECP=SBK $END 
 $SYSTEM TIMLIM=9999999999 MWORDS=200 $END 
 $SCF DIRSCF=.TRUE. $END 
 $STATPT NSTEP=1000 HESS=CALC $END 
 $GUESS GUESS=HUCKEL $END 
 $BASIS GBASIS=SBK $END 
 $ELPOT IEPOT=1 WHERE=PDC $END 
 $PDC PTSEL=CONNOLLY CONSTR=CHARGE $END 
 $FORCE PURIFY=.TRUE. PRTIFC=.TRUE. DECOMP=.TRUE. $END 
 $ZMAT IZMAT(1)=1,2,1,1,3,2,1,4,2,1,5,1,1,6,5,1,7,5,1,8,2,1,9,4,1,10,9, 
1,11,8,1,12,11,1,13,8,1,14,13,1,15,14,1,16,14,1,17,13,1,18,17,1,19,17, 
1,20,14,1,21,16,1,22,21,1,23,20,1,24,23,1,25,24,1,26,25,1,27,26,1,28,26, 
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1,29,26,1,30,29,1,31,29,1,32,29,1,33,32,1,34,33,1,35,33,1,36,33,1,37,20, 
2,3,2,1,2,4,2,1,2,5,1,2,2,6,5,1,2,7,5,1,2,8,2,1,2,9,4,2,2,10,9,4,2,11,8,2, 
2,12,11,8,2,13,8,2,2,14,13,8,2,15,14,13,2,16,14,13,2,17,13,8,2,18,17,13, 
2,19,17,13,2,20,14,13,2,21,16,14,2,22,21,16,2,23,20,14,2,24,23,20,2,25,24,23, 
2,26,25,24,2,27,26,25,2,28,26,25,2,29,26,25,2,30,29,26,2,31,29,26,2,32,29,26, 
2,33,32,29,2,34,33,32,2,35,33,32,2,36,33,32,2,37,20,14,3,4,2,1,3,3,5,1,2,3,3,6,5,1,2,3,7,5,1,2,3,8,
2,1,3,3,9,4,2,1,3,10,9,4,2,3,11,8,2,1,3,12,11,8,2,3,13,8,2,1,3,14,13,8,2,3,15,14,13,8,3,16,14,13,8,
3,17,13,8,2,3,18,17,13,8,3,19,17,13,8,3,20,14,13,8,3,21,16,14,13,3,22,21,16,14,3,23,20,14,13,3,2
4,23,20,14,3,25,24,23,20,3,26,25,24,23,3,27,26,25,24,3,28,26,25,24,3,29,26,25,24,3,30,29,26,25,
3,31,29,26,25,3,32,29,26,25,3,33,32,29,26,3,34,33,32,29,3,35,33,32,29,3,36,33,32,29,3,37,20,14,
13, 
 $END 
 $DATA 
 
File 15. Hessian Calculation for ascorbic acid for NAMD parameterization (truncated) 
 
 $CONTRL SCFTYP=RHF RUNTYP=HESSIAN ICHARG=0 MULT=1 COORD=ZMT 
NZVAR=54 $END 
 $CONTRL MAXIT=75 $END 
 $SYSTEM TIMLIM=999999999 MWORDS=235 $END 
 $SCF DIRSCF=.TRUE. $END 
 $STATPT NSTEP=1000 $END 
 $BASIS GBASIS=N31 NGAUSS=6 $END 
 $ELPOT IEPOT=1 WHERE=PDC $END 
 $PDC PTSEL=CONNOLLY CONSTR=CHARGE $END 
 $FORCE PURIFY=.TRUE. PRTIFC=.TRUE. DECOMP=.TRUE. $END 
 $ZMAT IZMAT(1)=1,2,1,1,3,2,1,4,3,1,5,4,1,6,2,1,7,4,1,8,7,1,9,5,1,10,1, 
1,11,7,1,12,11,1,13,4,1,14,7,1,15,11,1,16,11,1,17,12,1,18,8,1,19,10,1,20,9,2,3,2,1,2,4,3,2,2,5,4,3,
2,6,2,3,2,7,4,3,2,8,7,4,2,9,5,4,2,10,1,2,2,11,7,4,2,12,11,7,2,13,4,3,2,14,7,4,2,15,11,7,2,16,11,7,2,
17,12,11,2,18,8,7,2,19,10,1,2,20,7,5,3,4,3,2,1,3,5,4,3,2,3,6,2,3,4,3,7,4,3,2,3,8,7,4,3,3,9,5,4,3,3,10
,1,2,3,3,11,7,4,3,3,12,11,7,4,3,13,4,3,2,3,14,7,4,3,3,15,11,7,4,3,16,11,7,4,3,17,12,11,7,3,18,8,7,4,
3,19,10,1,2,3,20,9,5,4, 
 $END 
 $ZMAT DLC=.TRUE. AUTO=.TRUE. $END 
 $DATA 
ascorbate toppar 
 
File 16. Hessian Calculation for mimosine for NAMD parameterization (truncated) 
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 $CONTRL SCFTYP=RHF RUNTYP=HESSIAN ICHARG=-1 MULT=1 COORD=ZMT 
NZVAR=63 $END 
 $CONTRL MAXIT=75 $END 
 $SYSTEM TIMLIM=999999999 MWORDS=235 $END 
 $SCF DIRSCF=.TRUE. $END 
 $STATPT NSTEP=1000 $END 
 $BASIS GBASIS=N31 NGAUSS=6 $END 
 $ELPOT IEPOT=1 WHERE=PDC $END 
 $PDC PTSEL=CONNOLLY CONSTR=CHARGE $END 
 $DATA 
 mimosine toppar 
 $FORCE PURIFY=.TRUE. PRTIFC=.TRUE. DECOMP=.TRUE. $END 
 $IZMAT IZMAT(1)=2,1,3,2,4,3,5,4,6,5,7,2,8,4,9,8,10,9,11,1,12,9,13,12,14,12, 
15,3,16,5,17,6,18,7,19,8,20,8,21,9,22,10,23,10,3,2,1,4,3,2,5,4,3,6,5 
,4,7,2,3,8,4,3,9,8,4,10,9,8,11,1,2,12,9,8,13,12,9,14,12,9,15,3,2,16,5,4,17,6,5,18,7,2,19,8,4,20,8,4,
21,9,8,22,10,9,23,10,9,4,3,2,1,5,4,3,2,6,5,4,3,7,2,3,4,8,4,3,2,9,8,4,3,10,9,8,4,11,1,2,3,12,9,8,4,13,
12,9,8,14,12,9,8,15,3,2,1,16,5,4,3,17,6,5,4,18,7,2,3,19,8,4,3,20,8,4,3,21,9,8,4,22,10,9,8,23,10,9,8
, 
 $END 
 
Appendix C 
 
NAMD Configuration Files 
 
File 17. General configuration file for the rapid equilibration of proteins 
 
# Equilibration run  
# 
# Monday May 26th, 2008 
# 
# Edward W. Lowe Jr 
# Merkler Research Group 
# Department of Chemistry 
# University of South Florida 
 
structure   dbm_for_equil.solvated.ionized.psf 
coordinates   dbm_for_equil.solvated.ionized.pdb 
seed 238897325 
binaryoutput  on 
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outputname   dbm_equilibration 
DCDfile   dbm_equilibration.dcd 
 
# output frequency 
outputenergies  1000 
outputtiming  1000 
restartfreq   10000 
DCDfreq   1000 
 
# integration parameters 
timestep   1.0 
rigidBonds   all 
nonbondedFreq  1 
fullElectFrequency 1 
stepspercycle  10 
 
# FF 
paraTypeCharmm  on 
parameters   par_all22_prot+Cu+ASC+MIM.inp  
parameters   par_all27_prot_lipid_na.inp 
exclude   scaled1-4 
1-4scaling   1.0 
switching   on 
cutoff   12.0 
switchdist   10.0 
pairlistdist  14.0 
 
# PBC 
cellBasisVector1 94.0  0.0  0.0 
cellBasisVector2  0.0 94.0  0.0 
cellBasisVector3  0.0  0.0 94.0 
cellOrigin   0.0  0.0  0.0 
wrapall  on 
 
# PME 
PME    on 
PMEGridSizeX  96 
PMEGridSizeY  96 
PMEGridSizeZ  96 
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# set temperature to 0 initially 
temperature   0 
 
# fix the backbone atoms and coppers in DBM 
fixedAtoms   on 
fixedAtomsForces  on 
fixedAtomsFile  dbm_for_equil.solvated.ionized.fixed.pdb 
fixedAtomsCol  B 
 
# turn on constraints for all of the alpha carbons in DBM 
constraints   on 
consRef   dbm_for_equil.solvated.ionized.constrained.pdb 
consKFile   dbm_for_equil.solvated.ionized.constrained.pdb 
consKCol   B 
 
# set piston will large damping 
langevin   on 
langevinDamping  5 
langevinTemp  310.15 
langevinHydrogen  off 
langevinPiston on 
langevinPistonTarget 1.01325 
langevinPistonPeriod 100 
langevinPistonDecay 50 
langevinPistonTemp 310.15 
useGroupPressure  yes 
 
# run one step to get into scripting mode 
minimize    0 
 
# turn off langevin pressure control dynamics 
langevinPiston off 
 
# minimize non-backbone atoms 
minimize    10000 
 
# minimize all atoms 
fixedAtoms   off 
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minimize    10000 
 
# heat with alpha carbons constrained 
run     10000 
 
# equilibrate volume with alpha carbons constrained (NPT on) 
langevinPiston on 
run     10000 
 
# equilibrate volume without constraints (1ns NPT) 
constraintScaling  0 
run     1000000 
 
 
 
File 18. General configuration file for long molecular dynamics simulations using multiple 
stepping algorithm 
 
# 
# PHM domain with bound coppers 
# NPT 80 ns run for asc binding site 
# Saturday July 20th, 2007 
# 
# Edward W. Lowe Jr 
# Merkler Research Group 
# Department of Chemistry 
# University of South Florida 
 
structure   PHM+ox_asc_solvated_ionized.psf 
coordinates   PHM+ox_asc_solvated_ionized.pdb 
bincoordinates  PHM+ox_asc_NPT_WRAPALL_17.restart.coor 
extendedsystem  PHM+ox_asc_NPT_WRAPALL_17.restart.xsc 
binvelocities  PHM+ox_asc_NPT_WRAPALL_17.restart.vel 
 
seed 238897325 
 
binaryoutput  on 
outputname   PHM+ox_asc_NPT_WRAPALL_18 
dcdfile   PHM+ox_asc_NPT_WRAPALL_18.dcd 
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# output frequency 
outputenergies  10000 
outputtiming  10000 
restartfreq   10000 
DCDfreq   10000 
 
# integration parameters 
timestep   1.0 
rigidBonds   all 
nonbondedFreq  2 
fullElectFrequency 4 
stepspercycle  20 
 
# FF 
paraTypeCharmm  on 
parameters   par_all22_prot+Cu+ASC.inp  
parameters   par_all27_prot_lipid_na.inp 
exclude   scaled1-4 
1-4scaling   1.0 
switching   on 
cutoff   12.0 
switchdist   10.0 
pairlistdist  14.0 
 
# PBC 
cellBasisVector1 120.0  0.0  0.0 
cellBasisVector2  0.0 120.0  0.0 
cellBasisVector3  0.0  0.0 120.0 
cellOrigin   0.0  0.0  0.0 
wrapall                on 
 
# PME 
PME    on 
PMEGridSizeX  122 
PMEGridSizeY  122 
PMEGridSizeZ  122 
 
# set piston will large damping 
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langevin   on 
langevinDamping  5 
langevinTemp  310.15 
langevinHydrogen  off 
langevinPiston on 
langevinPistonTarget 1.01325 
langevinPistonPeriod 100 
langevinPistonDecay 50 
langevinPistonTemp 310.15 
useGroupPressure  yes 
 
# run one step to get into scripting mode 
minimize 0 
 
# MD for 80 ns 
run 80000000 
 
File 19. General configuration file for steered molecular dynamics simulations 
 
# Edward W. Lowe Jr 
# Merkler Research Group 
# Department of Chemistry 
# University of South Florida 
# 
# Constant Velocity Pulling of reductant from PHM 
 
structure          PHM+ox_asc1_bound_solvated_ionized.psf 
coordinates         PHM+ox_asc1_bound_solvated_ionized.pdb 
bincoordinates   1.coor 
outputName          asc_pulling_1_022408 
set temperature     310 
firsttimestep       0 
 
# Input 
paraTypeCharmm    on 
parameters         par_all22_prot+Cu+ASC+MIM7.inp  
parameters   par_all27_prot_lipid_na.inp 
temperature          $temperature 
wrapWater            on 
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wrapAll              on 
 
# Force-Field Parameters 
exclude              scaled1-4 
1-4scaling           1.0 
cutoff               12. 
switching            on 
switchdist           10. 
pairlistdist         14. 
 
# Integrator Parameters 
timestep             1.0  ;# 1fs/step 
nonbondedFreq        1 
fullElectFrequency   1   
stepspercycle        10 
 
# Constant Temperature Control 
langevin             off     
langevinDamping      5      
langevinTemp         $temperature 
langevinHydrogen     no     
restartfreq          500      
dcdfreq              500 
xstFreq              500 
outputEnergies       100 
outputPressure       100 
 
# Fixed Atoms Constraint  
if {1} { 
fixedAtoms           on 
fixedAtomsFile       PHM+ox_asc1.SMD.ref 
fixedAtomsCol        B 
} 
 
 
SMD     on 
SMDFile    PHM+ox_asc1.SMD.ref 
SMDk    7 
SMDVel    0.0001 
Appendices 
 
175 
 
SMDDir -0.467180057326 -0.0811620777483 0.880429163064 
SMDOutputFreq   10 
 
run     1000000  
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Appendix D 
Monooxygenase X: Homology modeling results 
 
List of Figures 
(Figure ) 
 
 
Figure A.1. Monooxygenase X solvated and ionized prior to equilibration using NAMD. 
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(Figure ) 
 
Figure A.2. Monooxygenase X in ribbon representation of the secondary structure after 
equilibration with NAMD. 
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(Figure) 
 
Figure A.3. The rmsd versus time graph for the equilibration of Monooxygenase X using 
NAMD. Rmsd = 1.86.   
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Appendix E 
Equilibration results of oxidized PHM 
(Figure ) 
 
Figure A.4. PHM crystal structure in ribbon format solvated prior to equilibration with 
NAMD. 
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(Figure) 
 
 
Figure A.5. The time versus rmsd for the equilibration of oxidized PHM with NAMD.  Rmsd = 
2.057 
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Appendix F 
Dopamine β-Monooxygenase: Homology model 
(Figure ) 
 
Figure A.6. Dopamine β-monooxygenase homology model prior to refinement with NAMD.   
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(Figure ) 
 
 
Figure A.7. The rmsd versus time for the equilibration of dopamine β-monooxygenase 
homology model.  Rmsd = 1.86 
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Appendix G 
Synthesis of 14C-mimosine 
(Figure ) 
 
 
Figure A.8. Mimosine synthase reaction scheme. 
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(Figure ) 
 
 
Figure A.9. The synthetic scheme for O-acetyl-serine 
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(Figure ) 
 
 
Figure A.10. The scheme of the synthesis of dihydroxypyridine. 
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(Figure )
 
Figure A.11. The chromatogram of the separation of a mimosine standard solution by RP-
HPLC. 
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(Figure ) 
 
Figure A.12. The chromatogram of the RP-HPLC separation of dihydroxypyridine. 
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(Figure ) 
 
Figure A.13. The scheme of the enzymatic synthesis of 14C radiolabeled mimosine.  Note 
that * = 14C 
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(Figure ) 
 
Figure A.14. The chromatogram of the RP-HPLC separation of a 30-minute time point for 
the conversion of O-acetylserine and 3,4-dihydroxypyridine to mimosine by mimosine 
synthase. 
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